

Article

New Water-Soluble Copper(II) Complexes with Morpholine-Thiosemicarbazone Hybrids: Insights into the Anticancer and Antibacterial Mode of Action

Kateryna Ohui, Eleonora Afanasenko, Felix Bacher, Rachel Lim Xue Ting, Ayesha Zafar, Nuria Blanco-Cabra, Eduard Torrents, Orsolya Domotor, Nora V. May, Denisa Darvasiova, Eva A Enyedy, Ana D. Popovi#-Bijeli#, Johannes Reynisson, Peter Rapta, Maria Babak, Giorgia Pastorin, and Vladimir B. Arion

J. Med. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.jmedchem.8b01031 • Publication Date (Web): 03 Dec 2018

Downloaded from <http://pubs.acs.org> on December 5, 2018

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

1
2 **New Water-Soluble Copper(II) Complexes with Morpholine-Thiosemicarbazone**
3
4 **Hybrids: Insights into the Anticancer and Antibacterial Mode of Action**
5
6

7 Kateryna Ohui,^{a,‡} Eleonora Afanasenko,^{a,‡} Felix Bacher,^a Rachel Lim Xue Ting,^b Ayesha Zafar,^c Núria
8 Blanco-Cabra,^d Eduard Torrents,^d Orsolya Dömötör,^e Nóra V. May,^f Denisa Darvasiova,^g Éva A.
9 Enyedy,^e Ana Popović-Bijelić,^h Jóhannes Reynisson,^c Peter Rapta,^g Maria V. Babak,^{*,i,j} Giorgia
10 Pastorin,^b Vladimir B. Arion^{*,a}
11

12 ^a*University of Vienna, Institute of Inorganic Chemistry, Währinger Strasse 42, A-1090 Vienna, Austria,*
13

14 ^b*Department of Pharmacy, National University of Singapore, Singapore, 3 Science Drive 2, 117543*
15 *Singapore*
16

17 ^c*School of Chemical Sciences, University of Auckland, Auckland, New Zealand*
18

19 ^d*Bacterial Infections: Antimicrobial Therapies, Institute for Bioengineering of Catalonia (IBEC), The*
20 *Barcelona Institute of Science and Technology, Barcelona, Spain*
21

22 ^e*Department of Inorganic and Analytical Chemistry, University of Szeged, Dóm tér 7. H-6720 Szeged,*
23 *Hungary*
24

25 ^f*Research Centre of Natural Sciences, Hungarian Academy of Sciences, Magyar tudósok körútja 2. H-*
26 *1117, Budapest, Hungary*
27

28 ^g*Institute of Physical Chemistry and Chemical Physics, Slovak Technical University of Technology,*
29 *Radlinského 9, 81237 Bratislava, Slovak Republic*
30

31 ^h*Faculty of Physical Chemistry, University of Belgrade, 11158 Belgrade, Serbia*
32

33 ⁱ*Department of Chemistry, National University of Singapore, 3 Science Drive 2, 117543 Singapore*
34

35 ^j*Drug Development Unit, National University of Singapore, 28 Medical Drive, 117546 Singapore*
36

37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54 [‡] these co-authors contributed equally
55
56
57
58
59
60

1
2 **Keywords:** Thiosemicarbazones, Cu(II)-TSC, solution equilibrium, stability constants,
3
4 spectroelectrochemistry, molecular modelling, antitumor activity, antibacterial activity, mechanism of
5
6 action, cellular accumulation, ribonucleotide reductase inhibition, ER stress, apoptosis, cell cycle
7
8
9

10 **Abstract**

11
12 Six morpholine-(iso)thiosemicarbazone hybrids **HL**¹–**HL**⁶ and their Cu(II) complexes with good-to-
13 moderate solubility and stability in water were synthesized and characterized. Cu(II) complexes
14
15 [Cu(L¹⁻⁶)Cl] (**1**–**6**) formed weak dimeric associates in the solid state, which did not remain intact in
16
17 solution as evidenced by ESI-MS. The lead proligands and Cu(II) complexes displayed higher
18
19 antiproliferative activity in cancer cells than Triapine. In addition, complexes **2**–**5** were found to
20
21 specifically inhibit the growth of Gram-positive bacteria *S. aureus* with MIC₅₀ values at 2 to 5 µg/mL.
22
23 Insights into the processes controlling intracellular accumulation and mechanism of action were
24
25 investigated for **2** and **5**, including the role of ribonucleotide reductase (RNR) inhibition, endoplasmic
26
27 reticulum (ER) stress induction and regulation of other cancer signaling pathways. Their ability to
28
29 moderately inhibit R2 RNR protein in the presence of DTT is likely related to Fe chelating properties of
30
31 the proligands liberated upon reduction.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Progress in modern anticancer therapy has led to significant improvements in survival rates of cancer patients. However, even though more patients achieve remission nowadays, their life-span often remains short.¹ One of the major causes of cancer death is the malignant process itself, which is associated with extensive formation of metastases, but it is not commonly mentioned that a significant number of immunocompromised cancer patients die due to infections, such as pneumonia and peritonitis.² Despite that cancer patients are very prone to develop infections during chemotherapy, their preventive antibiotic treatment is hampered by additional adverse effects.³ However, recent clinical evidence demonstrated that benefits of antibiotic prophylaxis of cancer patients outweighed its risks.⁴ The simultaneous suppression of pathogenic microorganisms during anticancer chemotherapy could not only interrupt or abolish tumor growth but eventually protect cancer patients from infection. Hence, the development of novel drugs which exhibit dual anticancer and antibacterial properties in comparable concentration range would affect the malignant process and simultaneously decrease the risk of patients' death due to infection, febrile neutropenia and bacteraemia.

Both cancer and bacterial cells share similar properties, such as high rate of proliferation, rapid adjustment and quick spreading within the host and aggressive disease progression.⁵ In order to sustain such rapid proliferation, cancer and bacterial cells have to support DNA replication and production of RNA by increasing *de novo* nucleotide synthesis. Ribonucleotide reductase (RNR) is the key enzyme that catalyzes the reduction of ribonucleotides to their corresponding deoxyribonucleotides, thereby initiating DNA synthesis or repair, making it an important biomolecular target for drugs with anticancer and antibacterial properties.^{6,7} RNR consists of a large subunit (NrdA or R1), which contains the allosteric site that regulates and catalyzes substrate reduction, and a small subunit (NrdB or R2) with the diferric-tyrosyl radical cofactor, essential for the catalytic activity of the RNR enzyme. Small molecules,

1
2 that can sequester Fe(III) from the dinuclear metal center and/or scavenge the tyrosyl radical, inhibit R2
3
4 activity, thereby preventing *de novo* DNA synthesis in cancer cells and bacteria.
5
6
7

8
9 α -N-heterocyclic thiosemicarbazones (TSCs) are excellent transition metal chelators and have a broad
10
11 range of activities, including anticancer and antibacterial properties, which are believed to be at least
12
13 partially due to their RNR inhibition.⁸ To date, several TSC compounds, namely 3-amino-2-
14
15 pyridinecarboxaldehyde thiosemicarbazone (Triapine),^{9,10,11} di-2-pyridylketone 4-cyclohexyl-4-methyl-
16
17 3-thiosemicarbazone (DpC)^{12,13} and (*E*)-*N'*-(6,7-dihydroquinolin-8(5*H*)-ylidene)-4-(pyridine-2-
18
19 yl)piperazine-1-carbothiohydrazide (COTI-2)¹⁴ are undergoing phase I and II clinical trials against
20
21 various types of cancer. The main caveat in the use of TSCs is their high toxicity which is reflected in a
22
23 number of side-effects in clinical trials involving Triapine.^{9,10,11} Many studies have shown that Cu(II)-
24
25 TSC complexes often display better selectivity than their TSC proligands, which can be attributed to the
26
27 induction of different intracellular signaling pathways.¹⁵
28
29
30
31
32
33

34 Despite advances in the design and synthesis of new TSCs and Cu(II)-TSC complexes over the years,
35
36 these compounds are facing the problem of low aqueous solubility, thereby hampering their further
37
38 development. Therefore, the synthesis of water-soluble and cytotoxic TSCs and Cu(II)-TSC complexes
39
40 requires a thoughtful selection of the functional groups that can be attached at the TSC backbone without
41
42 reducing their biological activity.^{16,17,18,19,20} With the aim to reach the optimal combination of aqueous
43
44 solubility and high cytotoxicity, we designed new (iso)thiosemicarbazone-morpholine hybrids and their
45
46 Cu(II) complexes. Notably, morpholine moiety was chosen since it confers excellent water solubility,
47
48 which typically translates into an improved pharmacological effect. Additionally, morpholine
49
50 derivatives possess a broad spectrum of biological activities, including anticancer and antibacterial
51
52 therapeutic potential.²¹ For example, commercial anticancer drugs Aprepitant and Gefinitib, as well as
53
54 antibacterial drugs Finafloxacin and Levofloxacin include a morpholine fragment in their structures.
55
56
57
58
59
60





Chart 1. Line drawings of proligands $\mathbf{HL}^1\text{--}6$ and Cu(II) complexes $[\text{Cu}(\mathbf{L}^1\text{--}6)\text{Cl}]$ ($\mathbf{1--6}$) reported in this work. All proligands and Cu(II) complexes, but \mathbf{HL}^3 and $\mathbf{2}$, were investigated by single crystal X-ray crystallography.

Herein we report on the synthesis of water-soluble proligands $\mathbf{HL}^1\text{--}6$ and Cu(II) complexes $\mathbf{1--6}$ (Chart 1), which were characterized by analytical and various spectroscopic techniques. X-ray diffraction structures of \mathbf{HL}^1 , \mathbf{HL}^2 , $\mathbf{HL}^3\text{--}6$ and $\mathbf{1}$, $\mathbf{3--6}$ were established and solution equilibria studies for \mathbf{HL}^1 and Cu(II) complex formation with \mathbf{HL}^1 by pH-potentiometry, UV-vis, EPR and ^1H NMR spectroscopy, as well as electrochemistry were performed. Antiproliferative activity against human ovarian cancer A2780 and cisplatin resistant A2780cis cell lines, non-cancerous HEK293 cell line, as well as antibacterial activity against Gram-positive (*S. aureus*) compared to Gram-negative bacteria (*P. aeruginosa*) were investigated and structure-activity relationships discussed. The processes controlling cellular accumulation of $\mathbf{2}$ were investigated. Preliminary insights into the mode of action of $\mathbf{2}$ and $\mathbf{5}$,

1 including mouse R2 RNR inhibitory potential, studied by molecular modeling and tyrosyl radical
2 quenching monitored by EPR spectroscopy, as well as by Western Blotting and flow cytometry are also
3 presented.
4
5
6
7
8
9

10 **Results**

11 **Synthesis and characterization of (iso)thiosemicarbazone-morpholine hybrids and their Cu(II)**
12 **complexes.** The 5-methylmorpholine-pyridine-2-carboxaldehyde **H** was prepared in seven steps as
13 shown in Scheme 1 and the detailed synthesis is described in the Supporting Information. First pyridine-
14 2,5-dicarboxylic acid **A** was converted into diester **B** that was further reduced to the diol **C**. The latter
15 was selectively oxidized with SeO₂ to the aldehyde **D**. After protection of the aldehyde group the alcohol
16 **E** was converted into the chloride **F** that was further reacted with morpholine to give species **G**. Finally,
17 the hydrolysis of the methyl ester function in acidic conditions afforded the required aldehyde **H** for
18 condensation reactions with thiosemicarbazide, 4*N*-dimethyl-3-thiosemicarbazide, 4*N*-pyrrolydiny-3-
19 thiosemicarbazide, 4*N*-morpholinyl-3-thiosemicarbazide, 4*N*-phenyl-3-thiosemicarbazide and *S*-
20 methylisothiosemicarbazide hydroiodide to give the hybrids **HL**¹⁻⁶ (Scheme 1), respectively. One- and
21 two-dimensional NMR spectra were in agreement with the proposed structures for **HL**¹⁻⁶, enabling the
22 assignment of all ¹H and ¹³C resonances. The ESI mass spectra recorded in a positive ion mode showed
23 strong peaks corresponding to [M+H]⁺ and [M+Na]⁺ ions, respectively. The proligands **HL**¹⁻⁶ were
24 reacted with Cu(II) chloride dihydrate and triethylamine in 1:1:1 mole ratio in methanol to give
25 **[Cu(L¹⁻⁶)Cl]** (**1-6**) in 35–91% yields. Positive ion ESI mass spectra showed strong peaks attributed to
26 **[Cu(L¹⁻⁶)]⁺** ions. The structures of **1**, **3-6** were also established by single crystal X-ray diffraction (*vide*
27 *infra*).
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Scheme 1. Synthesis of 5-methylmorpholine-pyridine-2-carboxaldehyde. Reagents and conditions: (i) thionyl chloride, methanol, 0 °C → room temperature, 12 h;²² (ii) sodium borohydride, ethanol, acetone, potassium carbonate, chloroform, 0 °C, 1 h → reflux, overnight;²³ (iii) selenium dioxide, dioxane, water, 100 °C, 3 h;²⁴ (iv) trimethyl orthoformate, methanesulfonic acid, methanol, reflux, 48 h; (v) thionyl chloride, dichloromethane, -80 °C → room temperature, overnight; (vi) morpholine, triethylamine, THF/CH₂Cl₂ 1:1, 50 °C, overnight, purification by column chromatography; (vii) HCl, water, 60 °C, overnight.

X-ray Crystallography. The results of X-ray diffraction studies of **HL**¹, **HL**² and **HL**⁴⁻⁶ are shown in Figure S1, while those of [Cu(L¹)Cl] (**1**), [Cu(L³)Cl] (**3**), [Cu(L⁴)Cl] (**4**), [Cu(L⁵)Cl] (**5**) and [Cu(L¹)Cl(H₂O)] (**1'**), [Cu(L⁶)Cl] (**6**) in Figures 1 and 2, respectively. Selected bond distances and bond angles are quoted in Tables S1 and S2. The proligands adopted different isomeric configurations in the solid state depending on substituents at the terminal nitrogen atom of the thiosemicarbazide moiety. Complexes **1**, **3**, **4** and **5** form dimeric associates as shown in Figure 1 (co-crystallized solvent was omitted for clarity). Each Cu(II) ion has a distorted square-planar coordination geometry. Intermolecular contacts supporting the dimeric associates in the crystals are of different nature in **1** and **3-5**, respectively. The presence of long intermolecular contacts Cu···Cl or Cu···Cl and Cu···S (see legend to Figure 1) provides evidence of weak association of complexes in dimers, which most probably dissociate in solution with formation of monomeric species. There was no evidence from ESI mass spectra on the presence of dimeric species in solution.




Figure 1. ORTEP views of weak dimeric associates of (a) $[\text{Cu}(\text{L}^1)\text{Cl}]$ (**1**), (b), $[\text{Cu}(\text{L}^3)\text{Cl}]$ (**3**), (c) $[\text{Cu}(\text{L}^4)\text{Cl}]_2$ (**4**) and (d) $[\text{Cu}(\text{L}^5)\text{Cl}]$ (**5**).

Moreover, HL^1 reacts with CuCl_2 in aqueous solution with formation of five-coordinate complex $[\text{Cu}(\text{L}^1)\text{Cl}(\text{H}_2\text{O})]$ ($\mathbf{1}' \cdot 2\text{H}_2\text{O}$) (Figure 2b). The monomeric square-planar complex $[\text{Cu}(\text{L}^6)\text{Cl}]$ forms an

infinite chain via weak coordination of the morpholine oxygen atom of one complex to the Cu(II) atom of the next molecule as shown in Figure S2. The intermolecular Cu \cdots O contact is of 2.603(3) Å.




Figure 2. ORTEP views of (a) [Cu(L¹)Cl(H₂O)] (**1**) and (b) [Cu(L⁶)Cl] (**6**).

Solution Chemistry. In order to establish the presence of isomers of the proligands in aqueous solution and proton dissociation processes, in which these can be involved solution equilibrium studies have been performed. Likewise, the solution speciation of the copper(II) complexes, as well as their stability have been investigated to elucidate the species, which is the most stable and abundant at physiological pH. The proligand **HL**¹ (Chart 1) was chosen for the detailed solution equilibrium studies since it has the simplest structure and the best aqueous solubility among the proligands prepared. The presence of different isomers in solution was excluded by measurements of ¹H NMR spectra in 10% D₂O/90% H₂O (Figure S3), which showed only one set of signals for the proligand in accordance to its low (*C*₁) molecular symmetry. The proligand most probably adopts the *E* configuration found in the solid state (Figure S1). The same configuration was reported previously for the reference compound 2-formylpyridine thiosemicarbazone in polar solvents.²⁵ Proton dissociation processes were monitored in aqueous solution by pH-potentiometric and ¹H NMR titrations and three p*K*_a values were determined by both methods (Table S3). According to the obtained p*K*_a values **HL**¹ is mainly neutral (97% HL, 3% H₂L⁺) at physiological pH (Figure S4). Inspection of ¹H NMR spectra revealed stepwise deprotonation

of three functional groups in the following order: $N_{\text{pyridinium}}\text{H}^+ \rightarrow N_{\text{morpholinium}}\text{H}^+ \rightarrow N_{\text{hydrazine}}\text{H}$ (Figure S3).

The solution speciation of the Cu(II) complexes with HL^1 was characterized by the combined use of pH-potentiometry, UV-vis spectrophotometry (via charge transfer (CT) and d-d bands) and EPR spectroscopy. The spectral changes (Table S4, Figures 3a and S5) in the UV and visible regions measured at 1:1 metal-to-ligand ratio show the high-extent formation of a Cu(II) complex already at strongly acidic pH values (e.g. pH 1) and its stepwise deprotonation by increasing the pH. At pH 7.4 the dominant species is $[\text{CuL}]^+$ (Figure 3b).




Figure 3. UV-vis spectra recorded for the Cu(II)– HL^1 (1:1) system at various pH values (a), and concentration distribution curves and measured absorbance values at 346 nm (◆) and 440 nm (■) for the same system (b). $\{c_{\text{Cu(II)}} = c_{\text{lig}} = 121 \mu\text{M}; T = 298 \text{ K}; I = 0.10 \text{ M (KCl)}; l = 0.5 \text{ cm}\}$.

Due to the high stability of the Cu(II) complexes formed, the cumulative constant ($\log\beta$) for the $[\text{CuL}]^+$ species (Table S4) was determined via EDTA displacement studies (Figure S6). Then the $\text{p}K_{\text{a}}$ and the $\log\beta$ values for the other type of complexes ($[\text{CuLH}_2]^{3+}$, $[\text{CuLH}]^{2+}$, $[\text{CuLH}_1]$) were computed using each method and data were in a fairly good agreement (Table S4). It is worth noting that formation of a bis-ligand complex $[\text{CuL}_2]$ at ligand excess was also confirmed by the UV-vis CT and EPR titrations. The

d-d bands (Figure S5) recorded from pH 3.4 to 7.5 at 1:1 metal-to-ligand ratio revealed that the proton dissociation process of $[\text{CuLH}]^{2+} \rightarrow [\text{CuL}]^+$ is accompanied by rather weak spectral changes as most probably the non-coordinating morpholinium NH^+ is deprotonating. In order to further characterize the coordination modes of the various complexes in solution EPR parameters (Table S5) obtained by the deconvolution of the recorded spectra (Figure S7) were analyzed. The isotropic g and A values of $[\text{CuLH}]^{2+}$ and $[\text{CuL}]^+$ are quite similar indicating the like coordination mode.

Comparison of the EPR parameters of the Cu(II) complexes of **HL**¹ with those of 2-formylpyridine thiosemicarbazone²⁵ and Triapine²⁶ permitted to conclude that in the $[\text{CuLH}]^{2+}$ and $[\text{CuL}]^+$ complexes a typical coordination mode via the $\text{N}_{\text{pyridyl}}, \text{N}, \text{S}^-$ binding site is realized in accordance with the X-ray diffraction data. $[\text{CuLH}_2]^{3+}$ contains the diprotonated ligand in which the protons are attributed to the non-coordinating N^2H and morpholinium NH^+ moieties, while $[\text{CuLH}_1]$ is most probably a mixed hydroxido complex $[\text{CuL}(\text{OH})]$ formed by the deprotonation of water molecule coordinated in the fourth equatorial position. At ligand excess besides the bis-ligand complex a minor dinuclear species $[\text{Cu}_2\text{L}_3\text{H}]^{2+}$ was detected resulting in the weak exchange coupling between neighboring Cu(II) centers smearing out the expected hyperfine structure.

Cu(II)-TSC complexes undergo quasi-reversible one-electron reduction at biologically accessible potentials. In order to assess the redox properties of **1–6**, detailed electrochemical and spectroscopic studies in various solvents were performed using cyclic voltammetry as well as EPR–spectroelectrochemistry. Additionally, the UV–vis spectra of **1–5** were measured (Figure S8). Electrochemical and spectroscopic data are summarized in Table S6. Almost reversible one-electron cathodic reduction was observed for **1–5** in DMSO with half-wave redox potentials from -0.77 V to -0.81 V vs Fc^+/Fc (for comparison from -0.13 V to -0.17 V vs NHE) (Table S6 and Figure S9). In general, the values of redox potentials of **1–6** for the first reduction step decreased in the following rank

1
2 order ($E_{1/2}(\mathbf{5}) > E_{1/2}(\mathbf{2}) = E_{1/2}(\mathbf{3}) = E_{1/2}(\mathbf{4}) > E_{1/2}(\mathbf{1}) > E_{1/2}(\mathbf{6})$). The second reduction step occurred at –
3
4 1.8 V vs Fc⁺/Fc (–1.16 V vs NHE) and was less reversible indicating a ligand based reduction. This was
5
6 confirmed by the CVs of the corresponding proligands which exhibited the first reduction step at around
7
8 –1.9 V vs Fc⁺/Fc (not shown). In aqueous solutions the reduction potentials shifted to the less negative
9
10 values and reduction was less reversible as shown for **2** in Figure S10. Complex **6** exhibited different
11
12 redox behavior with the lowest electrochemical reversibility and the most negative reduction potential
13
14 of –0.86 V vs Fc⁺/Fc (–0.26 V vs NHE) (Figure S9c). Unlike the cathodic reduction, the anodic oxidation
15
16 of **1–6** was irreversible with potential values in the region from 0.4 to 0.8 V vs Fc⁺/Fc (0.68 V to 1.44 V
17
18 vs NHE). Similar response was observed for the corresponding proligand **HL**² (Figure S11), indicating
19
20 ligand based oxidation in **2**.
21
22
23
24
25
26

27 **The biologically accessible reduction of Cu(II)-TSC complexes is Cu-centered.** To investigate
28
29 whether the biologically accessible reduction is metal-centered, the reversible one-electron reduction of
30
31 **5** was further studied by *in situ* UV–vis-spectroelectrochemistry (Figure 4a). Upon cathodic reduction
32
33 at the first reduction peak two isosbestic points at 389 and 325 nm were detected. The spectral changes
34
35 of the S→Cu(II) charge transfer bands (~425 nm) clearly confirmed the reduction of Cu(II) to Cu(I).
36
37 Additionally, upon voltammetric reverse scan, reoxidation and a nearly full recovery of the initial optical
38
39 bands were observed, attesting the chemical reversibility of the cathodic reduction even at low scan rates
40
41 (Figure 4). To confirm the involvement of Cu(II) in the reduction processes, *in situ* EPR electrochemistry
42
43 of **1–6** in *n*Bu₄NPF₆/DMSO and water was performed, since metal-based reduction would result in the
44
45 formation of EPR-silent Cu(I) species (Figure 4b). As can be seen for electrochemical reduction of **2** in
46
47 *n*Bu₄NPF₆/DMSO in the region of the first one–electron reduction step (see inset in Figure 4b), a
48
49 significant decrease of EPR signal was observed in accord with the formation of diamagnetic Cu(I) d¹⁰
50
51 complex. For aqueous solutions the reversibility was significantly reduced, implying a more complex
52
53 mechanism involving the release of the proligand. However, by decreasing the scan rate and going to
54
55
56
57
58
59
60

the more positive potentials upon reverse scan, a partial recovery of the initial optical bands was also observed in aqueous solutions as shown for **2** in Figure S12. Thus, electrochemical data indicated a likely reduction of Cu(II)-TSC complexes to Cu(I) species with the subsequent release of the proligands.




Figure 4. Spectroelectrochemistry of **2** in $n\text{Bu}_4\text{NPF}_6/\text{DMSO}$ in the region of the first cathodic peak. (a) Potential dependence of UV-vis spectra with respective cyclic voltammogram (Pt-microstructured honeycomb working electrode, scan rate $\nu = 5 \text{ mV s}^{-1}$); (b) evolution of UV-vis spectra in 2D projection in forward scan (Inset: EPR spectra measured at the first reduction peak using Pt mesh working electrode).

Lead TSCs and their Cu(II) complexes exhibited marked antiproliferative activity in a nanomolar concentration range. The *in vitro* anticancer activity of **1–6** and their respective TSCs was determined in ovarian carcinoma cells (A2780 and A2780cisR) and non-cancerous human embryonic kidney cells (HEK293) by the colorimetric MTT assay with an exposure time of 72 h. The IC_{50} values for **HL**¹–**HL**⁶

and **1–6** in comparison with Triapine, CuCl₂, Cu-Triapine and cisplatin are listed in Tables 1 and 2, respectively, and concentration-effect curves are depicted in Figure S13.

Table 1. Cytotoxicity of proligands **HL**^{1–6} and their *n*-octanol/water distribution coefficients (logD_{7.4})

Compound	IC ₅₀ [μM] ^a					logD _{7.4} ^d
	A2780	A2780cis	RF ^b	HEK293	SF ^c	
HL ¹	7.6 ± 1.9	13 ± 1	1.7	9.1 ± 1.7	1.2	+0.46 ± 0.01
HL ²	0.010 ± 0.001	0.035 ± 0.006	3.5	0.030 ± 0.005	3.0	+0.51 ± 0.02
HL ³	0.008 ± 0.002	0.028 ± 0.006	3.5	0.022 ± 0.005	2.8	+1.0 ± 0.1
HL ⁴	0.07 ± 0.01	0.76 ± 0.06	10.9	0.35 ± 0.05	5.0	+0.37 ± 0.04
HL ⁵	0.31 ± 0.08	1.1 ± 0.2	3.5	0.67 ± 0.06	2.2	≥2
HL ⁶	157 ± 21	426 ± 44	2.7	89 ± 2	0.6	+0.84 ± 0.01
Triapine	0.67 ± 0.22	1.1 ± 0.1	4.6	0.39 ± 0.05	0.6	n.d. ^e

^a 50% inhibitory concentrations (IC₅₀) in human ovarian carcinoma cell lines A2780 and A2780cisR and human embryonic kidney cell line HEK293, determined by means of the MTT assay after 72 h exposure. Values are means ± standard deviations obtained from at least three independent experiments, ^bResistance Factor (RF) is determined as IC_{50 (A2780cisR)}/IC_{50 (A2780)}, ^cSelectivity Factor (SF) is determined as IC_{50 (HEK293)}/IC_{50 (A2780)}, ^dDistribution coefficients between *n*-octanol and buffered aqueous solution determined at physiological pH by UV–vis spectroscopy. Values are means ± standard deviations obtained from at least three independent experiments, ^en.d. – not determined.

With the exception of **HL**¹ and **HL**⁶, the proligands demonstrated marked antiproliferative activity in a submicromolar to nanomolar concentration range in both A2780 and A2780cisR cells. The efficacy of compounds **HL**², **HL**³ and **HL**⁵ in cisplatin-resistant A2780cisR cells decreased by factor 3.5 in comparison to that in sensitive A2780 cells, whereas a 4.6- and 11-fold drop of activity was observed for Triapine and **HL**⁴, respectively. The activity of proligands **HL**^{1–6} and Triapine increased in the following rank order **HL**⁶ < **HL**¹ < **Triapine** < **HL**⁵ < **HL**⁴ << **HL**² ≈ **HL**³ (Table 1).

Table 2. Cytotoxicity of Cu(II)-TSC complexes **1–6**, CuCl₂ and cisplatin and their *n*-octanol/water distribution coefficients (logD_{7.4})

Compound	IC ₅₀ [μM] ^a					Cellular accumulation, ^d nmol Cu/ mg protein	logD _{7.4} ^e
	A2780	A2780cis	HEK293	RF ^b	SF ^c	A2780	
1	2.2 ± 0.1	13 ± 4	16 ± 2	5.9	7.3	0.63 ± 0.09	−0.81 ± 0.04
2	0.012 ± 0.002	0.030 ± 0.003	0.032 ± 0.008	2.5	2.7	3.9 ± 0.6	+0.30 ± 0.01
3	0.26 ± 0.02	0.60 ± 0.05	0.78 ± 0.20	2.3	3.0	2.2 ± 0.6	+0.86 ± 0.02
4	0.08 ± 0.01	0.26 ± 0.04	0.24 ± 0.02	3.3	3.0	3.2 ± 0.7	+0.12 ± 0.01
5	0.009 ± 0.002	0.017 ± 0.002	0.020 ± 0.003	1.9	2.2	4.1 ± 0.9	+1.49 ± 0.06
6	43 ± 3	62 ± 6	72 ± 0	1.4	1.7	0.47 ± 0.08	−0.23 ± 0.01
CuCl₂	83 ± 12	82 ± 3	187 ± 37	1.0	2.3	0.17 ± 0.05 ^f	n.d. ^g
Cu-Triapine^h	1.3 ± 0.1	29 ± 0.3	n.d.	22.3	-	n.d.	n.d.
Cisplatin	0.44 ± 0.13	4.6 ± 0.3	n.d.	10.5	-	-	−2.30 ± 0.79 ⁱ

^a 50% inhibitory concentrations (IC₅₀) in human ovarian carcinoma cell lines A2780 and A2780cisR and human embryonic kidney cell line HEK293, determined by means of the MTT assay after exposure for 72 h. Values are means ± standard deviations obtained from at least three independent experiments, ^bResistance Factor (RF) is determined as IC₅₀ (A2780cisR)/IC₅₀ (A2780), ^c Selectivity Factor (SF) is determined as IC₅₀ (HEK293)/IC₅₀ (A2780), ^d Cellular accumulation in A2780 cells, determined by ICP-MS after 24 h exposure at concentration of 1 μM. Values are means ± standard deviations obtained from at least three independent experiments, ^e Distribution coefficients between *n*-octanol and buffered aqueous solution determined at physiological pH by UV–vis spectroscopy. Values are means ± standard deviations obtained from at least three independent experiments, ^f Cellular accumulation of CuCl₂ was detected at concentration of 2.5 μM, ^g n.d. – not determined, ^h the IC₅₀ values (exposure for 72 h) were taken from the ref.: 27, ⁱ Log P_{o/w} value was taken from the ref. 28.

As can be seen in Table 2, with the exception of **3**, all Cu(II)-TSC complexes were equally or more cytotoxic than the respective proligands. The activity of complexes **1–6** increased in the following order **6** < **1** < **3** < **4** << **2** < **5**, similar to the trend in electrochemical redox potentials for Cu-based reduction

1
2 step (Table S6). In order to compare the cytotoxicity of **1–6** with that of $[\text{Cu}(\text{H}_2\text{O})_6]^{2+}$, A2780 cells were
3
4 treated with aqueous solution of CuCl_2 . In agreement with the literature,²⁹ CuCl_2 revealed
5
6 antiproliferative activity in the high micromolar range, in contrast to high activity of **1–6**, which should
7
8 be regarded as individual entities with their own biological, pharmacokinetic and metabolic profiles.
9
10 Complexes **1–6** were up to ~50 times more cytotoxic than cisplatin in A2780 cells and up to ~270 times
11
12 more cytotoxic in A2780cisR cells. Additionally, the differences in cytotoxicity of **1–6** in A2780 and
13
14 A2780cisR cells were significantly lower than for **HL¹–HL⁶** and cisplatin, indicating high potential of
15
16 Cu(II) complexes for the treatment of cisplatin-resistant tumors. The most active TSC proligands and
17
18 their respective Cu(II) complexes were more selective towards A2780 cells over HEK293 cells;
19
20 however, they did not show any selectivity towards A2780cisR cells over HEK293 cells. On the
21
22 contrary, Triapine was significantly more cytotoxic towards non-cancerous HEK cells than A2780 or
23
24 A2780cis cells.
25
26
27
28
29
30

31 **Antiproliferative activity of Cu(II)-TSC complexes correlates with their cellular accumulation and**
32
33 **lipophilicity.** The ability of anticancer drugs to penetrate biological membranes, tissues and barriers
34
35 underlies their biological, pharmacokinetic and metabolic properties. These properties can be predicted
36
37 by calculating physicochemical characteristics of drug candidates using molecular descriptors.³⁰ In order
38
39 to estimate if the proligands **HL¹–HL⁶** and corresponding Cu(II) complexes demonstrate drug-like
40
41 properties, they were evaluated with main stream molecular descriptors, such as molecular weight
42
43 (MW), number of hydrogen bond donors and acceptors (HBD/HBA), *n*-octanol-water partition
44
45 coefficient (log P), polar surface area (PSA) and rotatable bonds (RB). The results are shown in Table
46
47 S7 in the Supporting Information. Based on the calculated physicochemical parameters, we determined
48
49 if novel compounds belonged to the *drug-like* chemical space, which is commonly defined by the well-
50
51 known Lipinski rule, or to the known drug space (KDS), which includes all small compounds in medical
52
53 use.³¹ As can be seen from Table S7, all compounds fell within the boundaries of *drug-like* chemical
54
55
56
57
58
59
60

1 space with the exception of **HL**⁴ which demonstrated higher HBA value, referring to KDS space. Based
2 on these results, novel compounds are expected to be sufficiently cell permeable. Following the
3 calculations, we determined the lipophilicity of all compounds experimentally ($\log D_{7.4}$, Tables 2 and 3).
4 It is known that cancer cells accumulate hydrophilic compounds to a smaller extent relative to
5 hydrophobic compounds, thereby affecting their activity. Hence, the differences in the lipophilicity of
6 compounds might be related to the observed trends in cytotoxicity of **1–6**. In general, with the exception
7 of morpholine derivative **HL**⁴, proligands which were obtained by systematic substitution at the terminal
8 thioamide nitrogen, demonstrated higher lipophilicity when compared to that of **HL**¹. As expected,
9 proligands were more lipophilic than the corresponding Cu(II) species, which are positively charged at
10 physiological pH (Figure 3b). Among Cu(II)-TSC complexes, only the least cytotoxic complexes **1** and
11 **6**, as well as cisplatin, demonstrated negative $\log D_{7.4}$ values, indicating their higher hydrophilicity. The
12 lipophilicity of **2–5** increased in the following order $4 < 2 < 3 < 5$, and correlated well with their
13 cytotoxicity in cancer cells, with the exception of **3**. Subsequently, we determined the total cellular
14 accumulation of Cu in A2780 cells by ICP-MS upon 24 h exposure to **1–6** in comparison with CuCl₂
15 (Table 4). The IC₅₀ values from MTT assays with 72 h drug exposure varied from nanomolar to high
16 micromolar concentrations; therefore, in the cellular accumulation experiment cells were treated with 1
17 μM of compounds of interest for 24 h to minimize cell detachment. The cellular accumulation of all
18 Cu(II)-TSC complexes was significantly higher than for CuCl₂, indicating the role of lipophilic TSC
19 ligands in the delivery of the complexes into the cells. The accumulation increased in the order $6 < 1 <$
20 $3 < 4 < 2 < 5$.

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50 **Cellular accumulation and efflux of Cu(II)-TSC complexes are energy- and/or temperature-**
51 **dependent processes.** Dependence of cytotoxicity on lipophilicity of **1–6** indicates that their cellular
52 accumulation at least partially occurs via passive diffusion. In order to gain additional insights into the
53 mechanisms controlling the accumulation of Cu(II)-TSC complexes, we investigated the effects of
54
55
56
57
58
59
60

temperature and various inhibitors on total cellular accumulation of **2** with the results shown in Figure 5. A2780 cells were treated with **2** at 3 μM for 30, 60 and 120 min at 37 and 4 $^{\circ}\text{C}$ and intracellular Cu content was measured by ICP-MS. Prolonged incubation at low temperatures may result in the changes in membrane fluidity, decreasing membrane permeability and restricting drug uptake;³² therefore, the shorter time point of 10 min was also included. The cellular accumulation of **2** dramatically decreased at low temperature even after 10 min treatment, indicating the involvement of active carrier-mediated transport or facilitated diffusion. Likewise, the decrease of cellular accumulation at low temperatures has been reported for both Cu(II)-TSC complexes and metal-free TSCs.^{33,34} To further clarify whether the uptake of **2** requires energy, the cellular ATP production was blocked by incubating cells in a saline solution (HBSS), resulting in total starvation and rapid reduction of intracellular ATP content, and/or by addition of oligomycin, leading to the inhibition of oxidative phosphorylation.




Figure 5. Effects of temperature and inhibitors on the accumulation of **2** in A2780 cells. Intracellular content was determined by ICP-MS: a) A2780 cells were treated with **2** (3 μM) at 37 or 4 $^{\circ}\text{C}$ for the indicated time periods. b) A2780 cells were pre-treated with oligomycin (5 μM), and/or pre-incubated in HBSS for 1 h, or pre-treated with cycloheximide (100 μM) for 4 h and subsequently co-treated with **2** (3 μM) for 1 h. The presence of inhibitors did not show any effects on the intracellular Cu level of untreated A2780 cells (data not shown). Statistical analysis was performed by two-tailed T-test using GraphPad Prism software (GraphPad Software Inc., CA) with $p < 0.05$ considered as significant (* $p < 0.05$, ** $p < 0.01$).

1
2 When A2780 cells were pre-treated with 5 μM of oligomycin for 1 or 4 h and subsequently co-treated
3
4 with 3 μM of **2**, the intracellular Cu levels were not affected, even though the mitochondrial respiration
5
6 of the cancer cells was successfully inhibited (data not shown). However, when A2780 cells were starved
7
8 in HBSS for 1 h and subsequently treated with 3 μM of **2** for 1 h, an increase in intracellular Cu content
9
10 was observed. Co-treatment of **2** with 5 μM of oligomycin in HBSS did not result in a further increase
11
12 of intracellular Cu levels. The increase of Cu content in HBSS-starved cells might stem from the
13
14 inhibition of energy-dependent efflux processes. In order to assess the role of proteins in both cellular
15
16 accumulation and efflux of **2**, A2780 cells were pre-treated with cycloheximide, which is a known
17
18 inhibitor of protein synthesis. Significant increase of intracellular Cu content was observed, similar to
19
20 HBSS starvation, providing further evidence for the involvement of protein-dependent efflux processes.
21
22 Similar effects have been reported for related Cu(II)-TSC complexes.³³ Accumulated data provide
23
24 evidence that cellular accumulation of **2** occurs via carrier-facilitated diffusion, which might co-exist
25
26 with passive permeation through the lipid bilayer.³⁵ The efflux processes, however, are actively
27
28 mediated by proteins and upon inhibition of protein synthesis or energy production a strong increase of
29
30 intracellular Cu concentration was observed.
31
32
33
34
35
36
37

38 **Cu(II)-TSC complexes demonstrated high antibacterial activity against *S. aureus* in a comparable**
39
40 **concentration range to ciprofloxacin.** The antibacterial activity of **HL¹–HL⁶** and **1–6** on planktonic
41
42 cells of *P. aeruginosa* and *S. aureus* was investigated by determination of MIC₅₀ and MIC₁₀₀ values
43
44 (Table 3). Overall, compounds showed a higher antimicrobial activity against Gram-positive (*S. aureus*)
45
46 compared to Gram-negative bacteria (*P. aeruginosa*). The highest activity against *S. aureus* was
47
48 observed for **2–5**, which specifically inhibited its growth with MIC₅₀ values ranging between 2 and 5
49
50 $\mu\text{g/mL}$ and completely abolished its growth at 10 $\mu\text{g/mL}$ (MIC₁₀₀). This activity is comparable but
51
52 slightly lower than the antibacterial activity of a well-known benchmarked antibiotics ciprofloxacin
53
54
55
56
57
58
59
60

(CPX). On the contrary, *P. aeruginosa* exhibited high resistance to most of the compounds tested with the exception of **HL**² and **2** with MIC₅₀ values at 70 and 50 μg/mL, respectively.

Table 3. Antibacterial activity of **HL**¹⁻⁶ and **1-6**^a

	<i>S. aureus</i> (μg/mL)		<i>P. aeruginosa</i> (μg/mL)	
	MIC ₅₀	MIC ₁₀₀	MIC ₅₀	MIC ₁₀₀
HL ¹	100	>400	NA	NA
HL ²	10	400	50	100
HL ³	10	300	100	NA
HL ⁴	100	>400	NA	NA
HL ⁵	10	300	NA	NA
HL ⁶	NA	NA	NA	NA
1	100	>500	NA	NA
2	2	10	70	200
3	3	10	100	400
4	5	10	100	400
5	3	10	200	450
6	NA	NA	200	NA
Ciprofloxacin	0.5	1	0.5	2

^aSee experimental section for details. NA denotes no antibacterial activity detected (>500 μg/mL).

Compounds **HL**⁶ and **6** based on S-methylisothiosemicarbazide were completely devoid of antibacterial activity and no inhibition of bacterial growth was observed at the whole concentration range tested. Interestingly, metal-free thiosemicarbazones **HL**¹⁻⁵ displayed relatively low antibacterial activity (MIC₁₀₀ > 300 μg/mL), which was significantly enhanced upon coordination to Cu(II). Subsequently, the mode of action of the most active compounds **2-5** was evaluated in *S. aureus* and *P. aeruginosa* using the Live/Dead viability assay. As shown in Figure 6, compounds **2-5** greatly reduced cell

replication, reflected by the lower number of cells compared to the untreated sample and high percentage of PI-stained cells, indicating compromised cell membrane allowing the penetration of propidium iodide and a bacteriostatic action of these compounds.





Figure 6. Live/dead bacterial cells are shown by staining with green fluorescence indicating live cells and red fluorescence indicating dead cells.

TSCs and their Cu(II) complexes are located in a close proximity to the active site of mouse R2 RNR protein. Next, the RNR inhibitory potential of the TSC proligands **HL**¹–**HL**⁶ and their corresponding Cu(II) complexes **1**–**6** was investigated. The proligands **HL**¹–**HL**⁶ and Cu(II) complexes **1**–**6** were docked into the crystal structure of mouse R2 RNR subunit (PDBid:1W68)³⁶ using GOLD software.³⁷ To predict the binding of **1**–**6**, the GoldScore function was used and its parameters were modified to include Cu since they are not in GOLD's database.³⁸ The scoring functions are presented in Table S8. Overall, similar docking results were observed for all proligands and their Cu(II) complexes, suggesting a plausible binding to the mouse R2 protein. The compounds were deeply embedded into the pocket of the R2 subunit, close to the diferric center (Fe₂O), and the enzymatically essential tyrosyl residue (Tyr177). The docked configuration of **5** in comparison with Triapine into the binding site is

1
2 shown in Figure 7. An overlap with Triapine was predicted, resulting in a partial reproduction of a
3
4 hydrogen-bonding pattern (Figure S14, Table S8).
5



6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28 **Figure 7.** The overlay of docked configurations of Cu(II) complex **5** (grey) and Triapine (green) in the binding site of the
29 mouse R2 RNR protein (PDB ID: 1W68). The surface is rendered. Blue and brown depict hydrophilic and hydrophobic areas,
30 respectively.
31
32

33
34
35 **Lead TSCs and their Cu(II) complexes cause moderate inhibition of a mouse R2 RNR protein in**
36 **a reducing environment as a result of iron chelation.** The effects of the most cytotoxic complexes **2**
37 and **5**, and the corresponding proligands **HL²** and **HL⁵**, on the mouse R2 tyrosyl radical were investigated
38 by EPR spectroscopy at 30 K. The proligands and their Cu(II) complexes were incubated with the mouse
39 R2 RNR protein at 1:1 protein-to-compound mole ratio at 298 K in the presence or absence of the
40 reducing agent dithiothreitol (DTT), and the time-dependent reduction of the tyrosyl radical was
41 monitored.³⁹ Tyrosyl radical reduction by the investigated compounds was observed only in the presence
42 of DTT. Upon incubation with **HL²**, **HL⁵** and **2**, **5**, 50% of tyrosyl radical was reduced within 90 s, after
43 which no further reduction was observed (Figure S15). Since the diferric center of the mouse R2 protein
44 is expected to be reduced upon addition of DTT,^{40,41} the ability of proligands **HL²** and **HL⁵** to form
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 stable Fe(II) complexes was investigated by monitoring these reactions by UV–vis measurements in
3
4 buffered aqueous solutions at pH 7.4. **HL**² and **HL**⁵ ($\lambda_{\text{max}} = 312$ and 320 nm, respectively) readily reacted
5
6 with $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ affording Fe(II) bis-ligand complexes ($\lambda_{\text{max}} = 373, 610$ nm and $\lambda_{\text{max}} = 385, 645$ nm,
7
8 respectively) at both 1:1 and 1:2 Fe-to-ligand mole ratios. Additionally, the formation of Fe(III)
9
10 complexes with the subsequent reduction by DTT was investigated (Figure S15). **HL**² and **HL**⁵ reacted
11
12 with $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ (at 1:1 or 1:2 Fe-to-ligand mole ratios) to give $[\text{Fe}^{\text{III}}(\text{L}^2)_2]^+$ and $[\text{Fe}^{\text{III}}(\text{L}^5)_2]^+$ complexes
13
14 ($\lambda_{\text{max}} = 378$ nm, 612 nm and $\lambda_{\text{max}} = 386$ nm, 635 nm, respectively). The formation of $[\text{Fe}^{\text{III}}(\text{L}^5)_2]^+$ species
15
16 was confirmed by ESI-MS (Figure S16). The absorption spectra of reduced forms were almost identical
17
18 to those of Fe(II) bis-ligand species, and to the previously reported spectra of other Fe^{II}-TSC
19
20 complexes.⁴²
21
22
23
24
25
26
27

HL² and **2** induced unfolded protein response (UPR), antioxidant defense and cell cycle
28
29 perturbations. In order to get further insight into the mechanism of action of **2**, Western Blotting of ER
30
31 stress-related protein markers, namely IRE1 α , CHOP, BiP/GRP78 and p-ERK, was performed (Figure
32
33 8). When A2780 cells were treated with increasing concentrations of **2** for 24 h, the dose-dependent
34
35 upregulation of IRE1 α and CHOP proteins, decrease of ER stress chaperone BiP/GRP78, as well as
36
37 phosphorylation of ERK were observed as a response to ER stress. To assess the effects of **2** on the cell
38
39 cycle, we examined the expression of cyclin D1 and cyclin B1 which serve as cell cycle regulatory
40
41 switches in actively proliferating cells and are required for cell cycle progression in G₁ and G₂ phases,
42
43 respectively. Complex **2** displayed significant inhibition of cyclin D1 expression, indicating cell cycle
44
45 arrest at G₁/S phase, whereas no changes in cyclin B1 expression were detected. Subsequently, we
46
47 compared the effects of **2** and the respective proligand **HL**² on the expression of p-ERK1/2 and the
48
49 marker of antioxidant defence NRF2. Both **HL**² and **2** demonstrated phosphorylation of ERK1/2;
50
51 however, the effects on NRF2 were markedly different. Whereas no increase of NRF2 expression was
52
53 observed, when cells were treated with **HL**², complex **2** induced increased expression of NRF2 even at
54
55
56
57
58
59
60

low concentration, indicating activated antioxidant defense, possibly as a result of ROS insult caused by Cu(II) reduction.




Figure 8. Western Blot analysis of various proteins. A2780 cells were treated with increasing concentrations of proligand **HL²** and complex **2** (corresponding to IC₅₀ value from MTT experiment with exposure time of 72 h) for 24 h. Total lysates were isolated and examined by Western Blot. Actin was used as a loading control.

HL² and 2 induced dose-dependent apoptosis accompanied by PARP cleavage and XIAP inhibition. To elucidate if observed cytotoxicity of new compounds described in this study was a result of apoptosis induction, we conducted Annexin V/PI apoptosis assay. In brief, fluorochrome-labeled Annexin V reagent is used for detection of membrane phosphatidylserine (PS), which translocates to the cellular surface from the inner side of plasma membrane in the event of early apoptosis. Simultaneously, propidium iodide (PI) is used for detection of later stages of apoptosis or necrosis, which are characterized by loss of membrane integrity and accumulation of PI inside the cells. A2780 cells were treated with 2IC₅₀ and 6IC₅₀ concentrations of **HL²** and **2** (IC₅₀ values were obtained from MTT experiment in A2780 cells with the exposure time of 72 h). Results are illustrated in Figure 9. Upon incubation of A2780 cells with increasing concentrations of **HL²** and **2**, the dose-dependent increase of apoptotic cells was observed.




Figure 9. Bar graphs showing the percentage of cell death due to apoptosis (left) and necrosis (right) in A2780 cells treated with increasing concentrations of **HL²**, **2** (2IC₅₀ and 6IC₅₀) and CuCl₂ and detected by Annexin V/PI apoptosis assay. Statistical analysis was performed by two-tailed T-test using GraphPad Prism software (GraphPad Software Inc., CA) with $p < 0.05$ considered as significant (* $p < 0.05$, ** $p < 0.01$).

At low concentrations both the proligand and Cu(II) complex induced a 2- to 3-fold increase of apoptotic cells in comparison with untreated cells (7.8 ± 1.8 %, 17.2 ± 3.9 % and 22.5 ± 5.3 % for untreated cells, **HL²** (2IC₅₀) and **2** (2IC₅₀), respectively). At high concentrations a further increase of apoptotic cells was observed (28.1 ± 4.0 % and 24.4 ± 7.8 .% for **HL²** (6IC₅₀) and **2** (6IC₅₀)). No significant differences between the apoptosis-inducing properties of the proligand **HL²** and **2** were noticed. When CuCl₂ was incubated with the cells at the concentration, corresponding to Cu content in **2** at 2IC₅₀, no induction of apoptosis was detected, which can be explained by poor cellular accumulation of CuCl₂. The proportion of necrotic cells was negligible and no significant deviation from untreated cells was detected; therefore, the induction of necrosis by **HL²** and **2** was ruled out. Subsequently, the effects of **HL²** and **2** on apoptotic signaling in cells were investigated by Western Blotting. A2780 cells were treated with increasing concentrations of the drug for 24 h, and the cleavage of poly (ADP-ribose) polymerase-1 (PARP) was investigated (Figure 8). Cleavage of poly (ADP-ribose) polymerase-1 (PARP) through suicidal proteases such as caspases has been widely accepted as an indicator of apoptosis.⁴³ As can be seen in Figure 8,

1
2 both **HL²** and **2** revealed a dose-dependent PARP cleavage, indicating apoptosis induction in agreement
3
4 with the results of Annexin V/PI assay. Additionally, expression of X-linked inhibitor of apoptosis
5
6 (XIAP) was markedly reduced in a dose-dependent manner upon treatment with increasing
7
8 concentrations of **2**.
9

10 11 12 13 **Discussion**

14
15 The diverse biological and chemical properties of Triapine and other TSCs, as well as their transition
16
17 metal complexes, have been extensively studied for decades.^{44,45,46,47,48,41,49,50,51} Their antiproliferative
18
19 and antibacterial activity varies greatly, from low nanomolar to high micromolar range, depending on
20
21 the substituents at the TSC backbone.^{16,20,52} Even though clinical trials demonstrated some benefits of
22
23 patient treatment with Triapine, its low aqueous solubility and high toxicity prevent it from further
24
25 clinical progress. In a continuous effort to improve the bioavailability and therapeutic profile of TSCs
26
27 and Cu(II)-TSC complexes, novel thiosemicarbazone hybrids with bioactive L-proline, homoproline,
28
29 piperazine or iminodiacetate moieties, using the molecular hybridization approach, have been designed
30
31 and synthesized.^{16,17,18,19,20} However, the improvement of the aqueous solubility was often accompanied
32
33 by a significant decrease in cytotoxicity. In this study, the attachment of N-substituted morpholine
34
35 moiety at the TSC backbone resulted in a simultaneous improvement of aqueous solubility and
36
37 cytotoxicity (up to ~50 times in comparison with Triapine). To ensure the selectivity of novel TSCs
38
39 towards cancer cells over healthy cells, their cytotoxicity against A2780 cancer cells and noncancerous
40
41 HEK293 cells was compared. It was shown that new compounds were 2–5 fold more toxic towards
42
43 cancer cells than healthy cells (Tables 1 and 2), whereas Triapine was more toxic towards noncancerous
44
45 cells, which is in agreement with its known high toxicity. The coordination of TSCs to Cu(II) resulted
46
47 in Cu(II)-TSC complexes with similar or improved antiproliferative activity. In general, when TSCs are
48
49 coordinated to Cu(II), an increase in cytotoxicity is observed;^{17,18,53} however, Cu(II)-Triapine complex
50
51 was shown to be significantly less cytotoxic than Triapine itself.²⁷ The activity of the Cu(II) complexes
52
53
54
55
56
57
58
59
60

1
2 **1–6** was in a good correlation with their lipophilicity, cellular accumulation, as well as their
3
4 electrochemical redox potentials (Tables S6 and 2). Interestingly, metal-free TSCs exhibited only low
5
6 antibacterial properties against *S. aureus*, whereas Cu(II)-TSC complexes revealed significant
7
8 antibacterial activity similar to that of the commonly used antibiotic ciprofloxacin (Table 4). These
9
10 results indicate that coordination of TSCs to Cu(II) improved their therapeutic potential. It should be
11
12 noted that the replacement of N,N,S- with N,N,N-chelating moiety in **6** resulted in a drop of cytotoxicity
13
14 and antibacterial activity, which is in agreement with the previously reported data.²⁰
15
16
17

18
19 The antiproliferative activity of Triapine and other TSC proligands is often related to their Fe-chelating
20
21 properties.⁵⁴ To sustain their high proliferation rate, cancer cells rely on increased uptake of Fe from Fe-
22
23 transporting proteins; therefore, Fe chelation is a valuable therapeutic strategy for cancer treatment.
24
25 Based on UV-vis and ESI-MS experiments, it was demonstrated that irrespective of metal-to-ligand
26
27 ratio, proligands **HL**² and **HL**⁵ readily reacted with Fe(III) to form [Fe^{III}(L²)₂]⁺ and [Fe^{III}(L⁵)₂]⁺ species,
28
29 which could be reduced to Fe(II) bis-ligand complexes by the reducing agent DTT. These results indicate
30
31 that morpholine-TSC hybrids, investigated in this study, may act as Fe chelators. Additionally,
32
33 spectroelectrochemical experiments revealed that under reducing conditions, the Cu(II)-TSC complexes
34
35 could undergo reversible reduction to Cu(I) species, with simultaneous release of proligands, suggesting
36
37 that these complexes may act as Fe chelators, also in cancer cells. In addition, the presence of the Cu(II)
38
39 ion in the cells may lead to the production of ROS *in vivo*, due to Cu(II)/Cu(I) redox cycling.⁵⁵
40
41
42
43
44
45

46
47 It is well known that one of the mechanisms contributing to the cytotoxic effects of Fe chelators is
48
49 inhibition of the RNR enzyme, which is highly expressed in cancer cells, and essential for their DNA
50
51 synthesis. The mechanism of RNR inhibition by Triapine has been extensively studied by several
52
53 research groups.^{41,46,47,51,56} It has been proposed that Triapine interferes with the assembly of the
54
55 diferroc-tyrosyl radical cofactor in R2, necessary for the catalytic activity of RNR.^{46,56} Moreover, it has
56
57
58
59
60

1
2 been shown that the presence of Fe is required for effective R2 inhibition,^{44,45} and that it is actually the
3
4 Fe(II)-Triapine species that is responsible for the R2-specific RNR inhibitory effect of
5
6 Triapine.^{41,46,47,51-58} The Fe(II)-Triapine complex may be formed by chelation of Fe from the differic
7
8 cofactor in R2 *in vitro*,^{44,41} and/or from intracellular iron pools *in vivo*.^{46,56} The potent inhibition of
9
10 human,⁴⁷ and mouse⁴¹ R2 RNR *in vitro* by catalytic amounts of Fe(II)-Triapine has been proposed to
11
12 involve ROS. Namely, ROS had been spin-trapped, and detected by EPR spectroscopy, in the aerobic
13
14 reaction between human R2 RNR and Fe(II)-Triapine, which had implicated that O₂ is important in
15
16 tyrosyl radical destruction, and that ROS may ultimately be responsible for the pharmacologic effects of
17
18 Triapine *in vivo*.⁴⁷ In another study of time-dependent tyrosyl radical reduction in mouse R2 by Triapine,
19
20 and its Zn, Ga, Cu, and Fe complexes, the requirement of O₂ in R2 inhibition was also suggested.⁴¹ This
21
22 was based on the observation that substoichiometric amounts of Fe(III)-Triapine relative to R2 (protein-
23
24 to-complex mole ratio, 5:1) reduced only 20% tyrosyl radical in anaerobic conditions, compared to
25
26 100% in aerobic conditions. However, more recently, in a different experimental setup, namely in the
27
28 presence of a 10-fold excess of Fe(II)-Triapine over R2 protein, the role of ROS (and O₂) in human R2
29
30 inhibition was excluded.⁵¹ This study showed that the principle mechanism of human R2 RNR inhibition
31
32 by Triapine, based on kinetic measurements of tyrosyl radical, and ⁵⁵Fe loss, is direct radical quenching,
33
34 in an iron-loaded protein. Furthermore, it implied that Fe(II)-Triapine can rapidly reduce the tyrosyl
35
36 radical, while leaving the protein in the met-state.
37
38
39
40
41
42
43
44

45
46 In order to investigate if R2 RNR could be the potential biomolecular target for the novel morpholine-
47
48 TSC hybrids, and their Cu(II) complexes, molecular docking studies, and R2 RNR tyrosyl radical
49
50 reduction kinetic experiments, were performed. It has been suggested that the efficiency of R2 inhibition
51
52 is likely to depend on the access of the inhibitors to the differic center of R2;^{41,47} therefore, we estimated
53
54 the likelihood of the binding of TSC proligands **HL**¹–**HL**⁶ and their corresponding Cu(II) complexes
55
56 **1**–**6** to the surface of the R2 protein. It was demonstrated that new TSCs, and their Cu(II) complexes
57
58
59
60

1 were deeply embedded into the pocket of the R2 protein and exhibited hydrogen bonding patterns similar
2 to Triapine (Figure 7). Based on the results of the molecular docking studies suggesting plausible binding
3 to the mouse R2 protein, the time-dependent tyrosyl radical reduction in the mouse R2 protein upon
4 incubation with the most cytotoxic complexes, **2** and **5**, and the corresponding proligands **HL**² and **HL**⁵,
5 at a 1:1 protein-to-compound ratio, was measured by EPR spectroscopy. Only in the presence of DTT
6 (which can reduce Fe(III) to Fe(II) in the R2 differic cofactor),⁴⁰ **HL**² and **HL**⁵ caused 50% tyrosyl
7 radical reduction (Figure S15a). These results show that R2 inactivation by **HL**² and **HL**⁵ is not as
8 efficient as with Triapine, which causes 100% tyrosyl radical loss in mouse R2 after 5 min (in the same
9 experimental conditions).⁴¹ The most plausible explanation for this observation is that different
10 mechanisms are likely to be involved in R2 inhibition by **HL**², **HL**⁵ and Triapine. The R2 inhibitory
11 activity of the corresponding Cu(II) complexes **2** and **5** was found to be similar to that of the proligands
12 (Figure S15a). This is likely due to the fact that in the presence of DTT, the reduction of Cu(II) to Cu(I)
13 leads to the release of the proligands, which is in agreement with the results of spectroelectrochemical
14 experiments (*vide supra*). Since the UV-vis, and ESI-MS experiments showed that **HL**² and **HL**⁵ act as
15 tridentate ligands, and form stable Fe(II)L₂ complexes (Figure S15), it is possible to propose that the
16 mechanism of R2 inhibition by the TSC proligands involves Fe chelation from the differic cofactor.
17 Based on the extent of tyrosyl radical reduction, it is tempting to speculate that the subsequently formed
18 Fe(II) complexes are not potent inhibitors like the Fe(II)-Triapine complex. However, as this was not
19 the aim of this paper, it is reasonable to refrain from any conclusions prior to the detailed mechanistic
20 studies of mouse, human, and p53 R2 RNR inhibition by the morpholine-TSC hybrids. Moreover, a
21 separate study should be dedicated only to the comparison of the inhibitory potentials of selected TSCs,
22 and their Fe(II) complexes, in order to comprehensively understand the structure-activity relationship,
23 which in turn may explain the mechanism of R2 RNR inhibition. Finally, even though R2 inhibition can
24 be partially attributed to the marked anticancer activity of **2** and **5**, other biomolecular targets are likely
25 to be involved (Figure 10).




Figure 10. Proposed molecular mechanism of complex **2**.

Fe homeostasis is an intrinsically complex process; hence, Fe sequestration results in the alteration of various biomolecular pathways. Besides RNR, Fe depletion affects multiple molecular targets including those regulating the cell cycle.⁵⁷ It has been reported that the expression of cyclin D1, which ensures the progression through the G₁/S phase, was strongly dependent on the cellular Fe status.⁵⁸ It is believed that in Fe-depleted conditions, down-regulation of cyclin D1 prevents cells from entering the S phase, where Fe is needed for the activity of the RNR enzyme and DNA synthesis.⁵⁹ Fe chelation by TSCs often results in the down-regulation of cyclin D1 and subsequent cell cycle arrest at the G₁/S phase.^{60,61} As expected, complex **2** was shown to induce strong dose-dependent down-regulation of cyclin D1, whereas the protein expression of cyclin B1, which is responsible for G₂/M progression, remained unchanged. In order to further investigate the potential biomolecular targets of Fe-chelating compounds of interest, we studied the phosphorylation of ERK protein, which belongs to the MAPK family. The MAP kinases occupy the central position in cell growth and apoptosis and each MAP kinase member plays a different

1
2 role in cellular responses.⁶² It was reported that some Fe chelators induced cancer cell death associated
3
4 with the activation of p38 MAPK and ERK.⁶³ Moreover, the MAPK-mediated cell death was
5
6 characterized by the decreased expression of cyclin D1.⁶⁴ Complex **2**, as well as the corresponding
7
8 proligand **HL**² caused dose-dependent phosphorylation ERK in line with its activation, suggesting that
9
10 MAPK pathway might be a potential mediator of the cell death, induced by this complex.
11
12
13
14

15
16 Recently, it was discovered that chelation and depletion of intracellular Fe leads to the activation of
17
18 certain ER stress-response proteins.^{65,66} Previously, several TSCs and their Cu(II) complexes were
19
20 reported to induce ER stress, characterized by UPR activation,^{67,68} ER expansion and release of
21
22 intracellular calcium.⁶⁹ Since under reducing conditions, the novel TSCs and their Cu(II) complexes
23
24 demonstrated formation of Fe(II)-TSC complexes, it may be suggested that they could possibly induce
25
26 sequestration of cellular Fe resulting in the ER stress. It occurs due to the accumulation of misfolded
27
28 and/or unfolded proteins in ER, resulting in the disruption of cellular homeostasis. In order to overcome
29
30 stress, cells activate a rescue program known as UPR, which operates via several signaling pathways,
31
32 namely ATF6, PERK and IRE1 α . However, in case of severe ER stress, the pro-survival program is
33
34 switched off and pro-apoptotic signaling takes place, characterized by the enhanced expression of CHOP
35
36 protein. Complex **2** was shown to induce dose-dependent increase in the expression of IRE1 α and CHOP
37
38 proteins, indicating the induction of UPR signaling as a result of ER stress. Cell treatment with **2** resulted
39
40 in a concentration-dependent decrease of BiP/GRP78 protein marker. The ER chaperon BiP/GRP78
41
42 plays a central role in the survival machinery and its overexpression is associated with tumor progression
43
44 and metastases.⁷⁰ The inhibition of BiP/GRP78 indicates severe ER stress, resulting in the suppression
45
46 of pro-survival chaperones. The antibacterial properties of novel Cu(II)-TSC complexes can be also
47
48 related to ER stress induction, since it was recently demonstrated *in vitro* and *in vivo* experiments that
49
50 chemical modulation of ER stress might result in the overload of its machinery that can be effective in
51
52 elimination of bacterial infection.⁷¹ Additionally, it was reported that efficient killing of methicillin-
53
54
55
56
57
58
59
60

1
2 resistant *S. aureus* was dependent on the induction of IRE1 α UPR pathway and required sustained
3
4 generation of ROS.⁷² Based on the observations that **2**, but not proligand **HL**² induced antioxidant
5
6 defence in cancer cells characterized by NRF2 induction, it may be speculated that the ability of **2**, but
7
8 not proligand **HL**², to induce oxidative and ER stress, may be related to the beneficial antibacterial
9
10 activity of Cu(II)-TSC complexes over metal-free TSCs. However, it is not clear yet why new complexes
11
12 **1–6** did not inhibit the growth of *P. aeruginosa* and their mechanism of action should be investigated in
13
14 more detail.
15
16
17
18
19

20 In order to cope with the severe perturbations imposed by drug treatment, cancer cells develop adaptive
21
22 responses to provide them with survival advantage. However, novel TSCs and their Cu(II) complexes
23
24 significantly disturbed cellular life-death balance towards cell death resulting in the induction of
25
26 apoptosis. Both proligand **HL**², and complex **2** were demonstrated to induce apoptosis characterized by
27
28 PARP cleavage, decreased expression of XIAP and increased PS translocation. It should be noted that
29
30 XIAP is a determining factor of cisplatin chemoresistance in ovarian cancer cells as it effectively
31
32 suppresses apoptosis via caspase-3 and caspase-7 inhibition.⁷³ Therefore, the ability of **2** to decrease
33
34 XIAP expression is highly important and to the best of our knowledge has not been previously reported
35
36 for TSCs and metal thiosemicarbazones, with the exception of Triapine.⁷⁴ Some TSCs and their
37
38 respective Cu(II) complexes have been reported to simultaneously induce various types of cell death
39
40 including apoptosis,^{75,76} autophagy^{76,77} and methuosis, which is a very special form of non-apoptotic cell
41
42 death involving massive cytoplasmic vacuolization.⁷⁸ Therefore, induction of other forms of cell death
43
44 by new TSCs and their Cu(II) complexes presented in this study cannot be excluded. The results show
45
46 that the attachment of the morpholine moiety at the TSC backbone and the subsequent coordination to
47
48 Cu(II), resulted in new drug candidates, likely with better therapeutic profile than Triapine and a
49
50 promising potential for further clinical development.
51
52
53
54
55
56
57
58
59
60

Conclusions

One of the reasons hindering the clinical development of Cu(II) thiosemicarbazone complexes is their low aqueous solubility. The decoration of the TSC backbone with functional groups that increase the aqueous solubility and bioavailability often results in a significant decrease of the compound activity. In this work, attachment of a morpholine moiety to 2-formylpyridine (iso)thiosemicarbazone in position 5 of 2-formylpyridine moiety yielded new water-soluble TSC-morpholine hybrids and their Cu(II) complexes, which demonstrated high antiproliferative activity against cisplatin-sensitive and cisplatin-resistant ovarian carcinoma cells, in a nanomolar to submicromolar concentration range. Sufficient aqueous solubility of the new compounds enabled the study of their solution behavior and electrochemical properties under conditions similar to the intracellular environment. Solution speciation studies of **1** revealed that the dissociation of the complex does not occur at the physiological pH, even at micromolar concentrations, indicating its high stability in aqueous media. However, under reducing conditions associated with the cancer cell environment, the reversible reduction of Cu(II) with subsequent release of the proligand within the biologically accessible electrochemical window is plausible. Since the R2 RNR protein is believed to be one of the biomolecular targets of TSCs, and the fact that the proligands form 2:1 complexes with Fe(II), the chelation of Fe(II) from R2 was expected. The Cu(II)-TSCs and their corresponding proligands showed only moderate Tyrosyl radical reduction in mouse R2. Therefore, the marked anticancer activity of the compounds investigated in this work was not solely related to their RNR inhibitory potential, but also to the induction of apoptosis as a result of ER stress, MAPK activation and cell cycle perturbations. Studies of the mechanisms controlling cellular accumulation of the lead drug **2** have shown that it accumulates in cancer cells as a result of passive and/or facilitated diffusion. Finally, it was discovered that coordination of TSC ligands to Cu(II) resulted in a significant enhancement of their antibacterial properties against *S. aureus*. The combination of excellent antiproliferative and antibacterial activity, as well as water-solubility, is a sound basis for further development of this class of Cu(II) thiosemicarbazones as dual pharmaceutical agents.

Experimental

1. Chemicals. 2,5-Pyridinecarboxylic acid was purchased from Alfa Aesar. Ethylenediaminetetraacetic acid (EDTA), KOH and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) were purchased from Sigma-Aldrich in puriss quality. KCl, CuCl₂, hydrochloric acid and *n*-octanol are products of Molar Chemicals. CuCl₂ stock solution was prepared from anhydrous CuCl₂ and water and its exact concentration was determined by complexometry through the EDTA complex. All solvents were of analytical grade and used without further purification. Milli-Q water was used for sample preparation. The synthesis of the 5-methylmorpholine-pyridine-2-carboxaldehyde **H** (Scheme 1) is described in detail in Supporting Information. Chemical grade cisplatin (1 mg/mL) was purchased from Hospira Pty Ltd (Melbourne, Australia). IGEPAL CA-630, DL-dithiothreitol (DTT), tetramethylethylenediamine (TEMED), sodium deoxycholate, non-fat dried milk bovine, TWEEN® 20, ponceau S, propidium iodide (PI) were purchased from Sigma-Aldrich (St Louis, MO, USA). Thiazolyl Blue tetrazolium bromide (MTT) was purchased from Alfa Aesar. Tris was purchased from Vivantis Technologies. Glycine, Hyclone™ Trypsin Protease 2.5% (10×) solution, RPMI 1640, DMEM medium, Fetal bovine serum (FBS), Bovine Serum Albumin (BSA), Hank's Balanced Salt Solution (HBSS) and Pierce™ Protease and Phosphatase Inhibitor Mini Tablets were purchased from Thermo Fisher Scientific. Hyclone™ Dulbecco's Phosphate-Buffered Saline (10×), were purchased from GE Healthcare Life Sciences. Biorad protein assay dye reagent concentrate, 30% Acrylamide/Bis solution, 5× Laemmli Sample Buffer, Nitrocellulose Membrane (0.2 μm) were purchased from Bio-rad Laboratories. Luminata™ Classico and Crescendo Western HRP substrate were purchased from Merck Millipore Corporation. Milli-Q-grade purified water was obtained from a Milli-Q UV purification system (Sartorius Stedim Biotech S.A., Aubagne Cedex, France). All antibodies were obtained from Cell Signaling Technologies (Beverly, MA, USA). Nitric acid (65% to 71%, TraceSELECT Ultra) for ICP-MS analysis and *n*Bu₄NPF₆ for cyclic voltammetry experiments were obtained from Fluka (Sigma Aldrich) and used without further purification. Cu and In standards for ICP-MS measurements were obtained from CPI

international (Amsterdam, The Netherlands). Cycloheximide, oligomycin, annexin V-FITC apoptosis detection reagent (500X) were purchased from Abcam (Cambridge, UK).

2. Synthesis of proligands.

The yields, m.p. and analytical data for **HL¹–HL⁶** and **1–6** are presented in Tables S9 and S10. The experimental CHNS contents were within ± 0.4 with those calculated, providing evidence for $\geq 95\%$ purity.

5-(morpholinomethyl)pyridine-2-carboxaldehyde thiosemicarbazone (HL¹). 5-morpholinomethylpyridine-2-carboxaldehyde (0.29 g, 1.41 mmol), thiosemicarbazide (0.13 g, 1.41 mmol) and EtOH (5 mL) were mixed in a 25 mL Shlenk tube. The reaction mixture was stirred at 78 °C overnight. The next day the reaction mixture was cooled to room temperature and stored at 4 °C for 4 h. The white crystalline precipitate was filtered off, washed with cold EtOH and dried in vacuo. Yield: 0.34 g. ¹H NMR 500 MHz (DMSO-d₆, δ , ppm): ¹H NMR (500 MHz, DMSO) δ 11.62 (s, 1H, NH¹⁶), 8.48 (d, $J = 1.3$ Hz, 1H, H⁶), 8.34 (s, 1H, NH¹⁹), 8.24 (d, $J = 8.1$ Hz, 1H, H³), 8.15 (s, 1H, NH¹⁹), 8.09 (s, 1H, H¹⁴), 7.74 (dd, $J = 8.2, 1.7$ Hz, 1H, H⁴), 3.59 – 3.54 (m, 4H, H¹⁰, H¹²), 3.51 (s, 2H, H⁷), 2.36 (s, 4H, H⁹, H¹³). ¹³C NMR (126 MHz, DMSO) δ 178.74 (C_q, C¹⁷), 152.73 (C_q, C²), 150.12 (CH, C⁶), 142.85 (CH, C¹⁴), 137.51 (CH, C⁴), 134.23 (C_q, C⁵), 120.23 (CH, C³), 66.57 (2CH₂, C¹⁰, C¹²), 59.74 (CH₂, C⁷), 53.49 (2CH₂, C⁹, C¹³). IR (ATR, selected bands, $\tilde{\nu}_{\max}$): 1612, 1527, 1468, 1400, 1339, 1274, 1102, 1004, 938, 859, 626 cm⁻¹.

5-(morpholinomethyl)pyridine-2-carboxaldehyde 4,4-dimethyl-3-thiosemicarbazone (HL²). 5-(morpholinomethyl)pyridine-2-carboxaldehyde (0.29 g, 1.41 mmol) and 4,4-dimethyl-3-thiosemicarbazide (0.17 g, 1.41 mmol) were dissolved in EtOH (5 mL) and stirred in a Shlenk tube at 78 °C for 2 h until the solution became clear. The reaction mixture was left to stand at 4 °C for 6 h. The yellow crystalline precipitate was filtered off, washed with cold EtOH and dried in vacuo. Yield: 0.25 g. ¹H NMR (500 MHz, DMSO) δ 15.08 (s, 1H, NH¹⁶), 8.71 (s, 1H, H³), 8.49 (s, 1H, H⁶), 8.23 (d, 1H, H¹⁴), 7.76 (dd, $J = 13.9, 8.1$ Hz 1H, H⁴), 3.59 (s, 4H, H¹⁰, H¹²), 3.52 (s, 2H, H⁷), 3.38 (s, 4H, H²⁰, H²¹),

2.37 (s, 4H, H⁹, H¹³). ¹³C NMR (126 MHz, DMSO) δ 180.02 (C_q, C¹⁷), 153.06 (C_q, C²), 150.27 (CH, C⁶), 148.84 (CH, C³), 144.29 (CH, C¹⁴), 137.75 (CH, C⁴), 134.06 (C_q, C⁵), 66.61 (2CH₂, C¹⁰, C¹²), 59.77 (CH₂, C⁷), 53.53 (2CH₂, C⁹, C¹³), 42.72 (2CH₃, C²⁰, C²¹). IR (ATR, selected bands, $\tilde{\nu}_{\max}$): 1497, 1443, 1362, 1303, 1209, 1158, 1108, 1064, 1003, 901, 862, 716, 627 cm⁻¹.

5-(morpholinomethyl)pyridine-2-carboxaldehyde *N*-pyrrolidinylthiosemicarbazone (HL³). 5-(morpholinomethyl)pyridine-2-carboxaldehyde (0.29 g, 1.41 mmol) and *N*-pyrrolidine-3-thiosemicarbazide (0.20 g, 1.41 mmol) were dissolved in EtOH (5 mL) and stirred in a Shlenk tube at 78 °C for 2 h until the solution became clear. The mixture was left to stand at 4 °C for 12 h. The yellow crystalline precipitate was filtered off, washed with cold EtOH and dried in vacuo. Yield: 0.36 g. ¹H NMR (500 MHz, DMSO) δ 11.23 (s, 1H, NH¹⁶), 8.49 (d, J = 1.4 Hz, 1H, H³), 8.20 (s, 1H, H⁶), 8.01 (dd, J = 8.0, 2.1 Hz, 4H, H²¹, H²²), 7.84 (s, 1H, H¹⁴), 7.77 (d, J = 1.9 Hz, 1H, H⁴), 3.76 (s, 4H, H²⁰, H²³), 3.59 (dd, J = 8.1, 5.3 Hz, 4H, H⁹, H¹³), 3.52 (s, 2H, H⁷), 2.42 – 2.32 (m, 4H, H¹⁰, H¹²). ¹³C NMR (126 MHz, DMSO) δ 177.02 (C, C¹⁷), 153.11 (C, C²), 150.17 (CH, C⁶), 149.02 (CH, C³), 143.48 (CH, C¹⁴), 139.44, (2CH₂, C²¹, C²²), 138.08 (CH, C¹⁶), 134.05 (C, C⁵), 119.43 (CH, C³), 66.62 (2CH₂, C⁹, C¹³), 59.91 (CH₂, C⁷), 53.53 (2CH₂, C²⁰, C²³), 40.00 (2CH₂, C¹⁰, C¹², overlapped with residual DMSO signal). IR (ATR, selected bands, $\tilde{\nu}_{\max}$): 1585, 1529, 1419, 1347, 1287, 1108, 1001, 855, 796, 741 cm⁻¹.

5-(morpholinomethyl)pyridine-2-carboxaldehyde *N*-morpholinylthiosemicarbazone (HL⁴). 5-(morpholinomethyl)pyridine-2-carboxaldehyde (0.29 g, 1.41 mmol) and *N*-morpholinyl-3-thiosemicarbazide (0.23 g, 1.41 mmol) were dissolved in EtOH (5 mL) and stirred in a Shlenk tube at 78 °C for 2.5 h until the solution became clear. Light-yellow crystals formed within 3 weeks at 4 °C after concentration of the reaction mixture. These were filtered off, washed with cold EtOH and dried in vacuo. Yield: 0.12 g. ¹H NMR (500 MHz, DMSO) δ 11.43 (s, 1H, NH¹⁶), 8.50 (d, J = 1.3 Hz, 1H, H⁶), 8.18 (s, 1H, H¹⁴), 7.83 (d, J = 8.1 Hz, 1H, H⁴), 7.78 (dd, J = 8.2, 1.9 Hz, 1H, H³), 3.98 – 3.91 (m, 4H, H²⁰, H²⁴), 3.72 – 3.66 (m, 4H, H²¹, H²³), 3.60 – 3.55 (m, 4H, H⁹, H¹³), 3.52 (s, 2H, H⁷), 2.36 (br. s, 4H, H¹⁰, H¹²). ¹³C NMR (126 MHz, DMSO) δ 181.27 (C_q, C¹⁷), 152.75 (C_q, C⁴), 150.33 (CH, C⁶), 144.44

(CH, C¹⁴), 137.83 (CH, C³), 134.27 (CH, C²), 119.60 (C_q, C⁴), 66.60 (2CH₂, C²¹, C²³), 66.48 (CH₂, C⁷), 59.73 (2CH₂, C⁹, C¹³).

5-(morpholinomethyl)pyridine-2-carboxaldehyde 4-phenylthiosemicarbazone (HL⁵). 5-(morpholinomethyl)pyridine-2-carboxaldehyde (0.29 g, 1.41 mmol) and 4-phenyl-3-thiosemicarbazide (0.24 g, 1.41 mmol) were dissolved in EtOH (5 mL) and stirred in a Shlenk tube at 78 °C for 3 h until the solution became clear. Then the reaction mixture was allowed to stand at 4 °C for 12 h. The yellow crystalline precipitate was filtered off, washed with cold EtOH and dried in vacuo. Yield: 0.32 g. ¹H NMR (500 MHz, DMSO) δ 12.02 (s, 1H, NH¹⁶), 10.24 (s, 1H, NH¹⁸), 8.52 (s, 1H, H⁶), 8.41 (d, *J* = 8.1 Hz, 1H, H³), 8.21 (s, 1H, H¹⁴), 7.78 (d, *J* = 10.1 Hz, 1H, H⁴), 7.56 (d, *J* = 8.6 Hz, 2H, H²¹, H²⁵), 7.40 (t, *J* = 7.9 Hz, 2H, H²², H²⁴), 7.24 (t, *J* = 7.4 Hz, 1H, H²³), 3.59 (s, 4H, H¹⁰, H¹²), 3.54 (s, 2H, H⁷), 2.38 (s, 4H, H⁹, H¹³). ¹³C NMR (126 MHz, DMSO) δ 176.84 (C_q, C¹⁷), 152.62 (C_q, C²), 150.25 (CH, C⁶), 143.45 (C_q, C¹⁴), 139.44 (C_q, C²⁰), 137.51 (CH, C⁴), 134.46 (C_q, C⁵), 128.59 (2CH, C²², C²⁴), 126.56 (2CH, C²¹, C²⁵), 120.68 (CH, C³), 66.62 (2CH₂, C¹⁰, C¹²), 53.54 (2CH₂, C⁹, C¹³), 40.00 (CH₂, C⁷). IR (ATR, selected bands, $\tilde{\nu}_{\max}$): 1592, 1505, 1466, 1338, 1291, 1188, 1105, 1060, 1000, 944, 909, 863, 791, 751, 689, 634 cm⁻¹.

5-(morpholinomethyl)pyridine-2-carboxaldehyde S-methylisothiosemicarbazone (HL⁶). To a solution of 5-(morpholinomethyl)pyridine-2-carboxaldehyde (0.29 g, 1.41 mmol) in EtOH (6 mL) was added a solution of S-methylisothiosemicarbazide hydroiodide (0.33 g, 1.41 mmol) in water (2 mL). Then the reaction mixture was heated to 60 °C and a solution of NaHCO₃ (0.118 g, 1.41 mmol) in water (4 mL) was added dropwise. When bubbles of CO₂ disappeared, the mixture was allowed to cool to room temperature. The solvent was removed under reduced pressure and the residue dissolved in water. The product was extracted with chloroform. After removal of the solvent the residue was dissolved in a small amount of EtOH and allowed to stand at -20 °C overnight. Light-brown crystalline product was obtained the next day. Yield: 0.14 g. ¹H NMR (500 MHz, DMSO) δ 8.49 (d, *J* = 1.4 Hz, 1H, H⁴), 8.21 (d, *J* = 8.1 Hz, 1H, H¹⁴), 8.17 (s, 1H, H⁶), 7.84 (d, *J* = 8.1 Hz, 1H, H³), 7.16 (s, 2H, H¹⁸), 3.60-3.55 (m,

1
2 8H, H⁹, H¹³), 3.51 (s, 2H, H⁷), 2.40 (br. s, 3H, H²⁰), 2.36 (d, J = 6.0 Hz, 8H, H¹⁰, H¹²). ¹³C NMR (126
3 MHz, DMSO) δ 164.19 (C, C¹⁷), 154.02 (C, C⁵), 151.84 (CH, C⁶), 150.12 (CH, C⁴), 137.35 (CH, C³),
4 133.89, (C, C²), 120.68 (CH, C¹⁴), 66.61 (2CH₂, C⁹, C¹³), 59.84 (CH₂, C⁷), 53.53 (2CH₂, C¹⁰, C¹²), 12.52
5
6 (CH₃, C²⁰). IR (ATR, selected bands, $\tilde{\nu}_{\max}$): 1600, 1497, 1472, 1335, 1290, 1111, 1069, 1015, 931, 870,
7
8 790, 752, 714, 626 cm⁻¹.

13 3. Synthesis of Cu(II) complexes.

14
15
16 [Cu(L¹)Cl] (1). To HL¹ (100 mg, 0.36 mmol) in MeOH (20 mL) was added triethylamine (50 μ l, 0.36
17 mmol) and then CuCl₂·2H₂O (60 mg, 0.36 mmol) in MeOH (5 mL) at 60 °C. The solution was stirred
18 for 5 min and left to stand at room temperature overnight. The precipitate formed was filtered off, washed
19 with cold EtOH and dried in air. Yield: 123 mg. IR (ATR, selected bands, $\tilde{\nu}_{\max}$): 1631, 1426, 1310,
20 1158, 1107, 1060, 907, 722, 688 cm⁻¹.

21
22
23 [Cu(L²)Cl] (2). To HL² (100 mg, 0.32 mmol) in MeOH (20 mL) was added triethylamine (44.5 μ L,
24 0.32 mmol) and then CuCl₂·2H₂O (54 mg, 0.32 mmol) in MeOH (5 mL) at 60 °C. The solution was
25 stirred for 5 min and left to stand at room temperature overnight. The precipitate formed was filtered off,
26 washed with cold EtOH and dried in air. Yield: 104 mg. IR (ATR, selected bands, $\tilde{\nu}_{\max}$): 1505, 1372,
27 1310, 1252, 1111, 1000, 913, 872, 749, 626 cm⁻¹.

28
29
30 [Cu(L³)Cl] (3). To HL³ (100 mg, 0.3 mmol) in MeOH (20 mL) was added triethylamine (42 μ l, 0.28
31 mmol) and then CuCl₂·2H₂O (50 mg, 0.3 mmol) in MeOH (5 mL) at 60 °C. The solution was stirred for
32 5 min and left to stand at room temperature overnight. The precipitate formed was filtered off, washed
33 with cold EtOH and dried in air. Yield: 74 mg. IR (ATR, selected bands, $\tilde{\nu}_{\max}$): 1444, 1375, 1281, 1242,
34 1111, 1004, 913, 885, 623 cm⁻¹.

35
36
37 [Cu(L⁴)Cl] (4). To HL⁴ (50 mg, 0.28 mmol) in MeOH (20 mL) was added triethylamine (20 μ l, 0.28
38 mmol) and then CuCl₂·2H₂O (25 mg, 0.28 mmol) in MeOH (5 mL) at 60 °C. The solution was stirred
39 for 5 min and left to stand at room temperature overnight. The precipitate formed was filtered off, washed
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

with cold EtOH and dried in air. Yield: 22 mg. IR (ATR, selected bands, $\tilde{\nu}_{\max}$): 1465, 1429, 1381, 1313, 1265, 1229, 1109, 1028, 932, 888, 860 cm^{-1} .

[Cu(L⁵)Cl] (5). To **HL⁵** (100 mg, 0.28 mmol) in MeOH (20 mL) was added triethylamine (39 μl , 0.28 mmol) and then $\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$ (47 mg, 0.82 mmol) in MeOH (5 mL) on heating. The solution was stirred for 5 min and left to stand at room temperature overnight. The precipitate formed was filtered off, washed with cold EtOH and dried in air. Yield: 67 mg. IR (ATR, selected bands, $\tilde{\nu}_{\max}$): 1600, 1550, 1493, 1417, 1182, 1111, 1000, 899, 863, 799, 752, 691 cm^{-1} .

[Cu(L⁶)Cl] (6). To **HL⁶** (100 mg, 0.34 mmol) in MeOH (20 mL) was added triethylamine (47 μl , 0.34 mmol). Then the reaction was heated to 40 °C and $\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$ (58 mg, 0.34 mmol) in MeOH (5 mL) was added. The solution was stirred for 5 min at 50 °C and left to stand at -20 °C overnight. The precipitate formed was filtered off, washed with ethanol, ether and dried in air. Yield: 75 mg. IR (ATR, selected bands, $\tilde{\nu}_{\max}$): 1599, 1491, 1431, 1320, 1115, 1035, 1004, 973, 911, 796, 724 cm^{-1} .

4. Solution equilibrium studies in aqueous phase

pH-potentiometric measurements. These measurements were performed as described previously.¹⁶ The initial volume of the samples was 10.0 mL. The ligand concentration was 1 mM and metal ion-to-ligand ratios of 1:1 – 1:3 were used. The exact concentration of the ligand stock solutions together with the proton dissociation constants were determined by pH-potentiometric titrations with the use of the computer program HYPERQUAD.⁷⁹ HYPERQUAD was also utilised to establish the stoichiometry of the complexes and to calculate the stability constants ($\log\beta(\text{M}_p\text{L}_q\text{H}_r)$). $\beta(\text{M}_p\text{L}_q\text{H}_r)$ is defined for the general equilibrium $p\text{M} + q\text{L} + r\text{H} \rightleftharpoons \text{M}_p\text{L}_q\text{H}_r$ as $\beta(\text{M}_p\text{L}_q\text{H}_r) = [\text{M}_p\text{L}_q\text{H}_r]/[\text{M}]^p[\text{L}]^q[\text{H}]^r$, where M denotes the metal ion and L the completely deprotonated ligand. The uncertainties (standard deviations, SD) of the equilibrium constants are shown in parentheses for the species determined in the present work.

1
2 **5. Instrumentation.** ICP-OES determination of Cu content was performed in Chemical, Molecular and
3
4 Analysis Centre, National University of Singapore with Optima ICP-OES (Perkin Elmer, Watham, MA,
5
6 USA). The absorbance of thiazolyl blue tetrazolium bromide (MTT) was measured by synergy H1
7
8 hybrid multimode microplate reader (Bio-Tek, Winoosky, VT, USA). Cu and Re contents in cells were
9
10 determined by Agilent 7700 Series ICP-MS (Agilent Technologies, Santa Clara, CA, USA). Flow
11
12 cytometry was performed on BD LSRFortessa Cell Analyzer (BD Biosciences, Franklin Lakes, NJ,
13
14 USA). Western blot images were generated from G:Box (Syngene, Cambridge, UK). The UV-vis
15
16 spectrophotometric measurements were performed on a Hewlett Packard 8452A diode array
17
18 spectrophotometer and a Thermo Scientific Evolution 220 spectrophotometer. CW-EPR spectra were
19
20 recorded with a BRUKER EleXsys E500 spectrometer. *In situ* ultraviolet-visible-near-infrared
21
22 (UV-vis-NIR) spectroelectrochemical measurements were performed on a spectrometer (Avantes,
23
24 Model AvaSpec-2048x14-USB2).

25
26
27 **6. UV-vis spectrophotometric, ¹H NMR, EPR and lipophilicity measurements.** UV-vis spectra were
28
29 recorded in the ranges 200–800 nm and 450–1050 nm, respectively. The path length was 0.5, 1 or 2 cm.
30
31 Stability constants of the complexes and the molar absorbance spectra of the individual species were
32
33 calculated with the computer program PSEQUAD.⁸⁰ The spectrophotometric titrations were performed
34
35 on samples containing the proligand with or without Cu(II) ions and the concentration of the proligand
36
37 was 120 μM – 1.4 mM. The metal-to-proligand ratios were 1:1 and 1:2 in the pH range from 1.0 to 11.5
38
39 at 25.0 ± 0.1 °C at an ionic strength of 0.10 M (KCl). pH values in the range 1.0–2.0, were calculated
40
41 from the strong acid and strong base content. The conditional stability constant of [CuL] at pH 6.0 (50
42
43 mM MES) for **1** was determined from competition titrations of the Cu(II) complex of EDTA with the
44
45 proligand **HL**¹. Samples contained 34 μM Cu(II) ion and 34 μM **HL**¹, and the concentration of the
46
47 EDTA was varied in the range of 0–83 μM. Absorbance data were recorded after 0.5 h incubation. ¹H
48
49 NMR studies for **HL**¹ were carried out on a Bruker Avance III HD Ascend 500 Plus instrument in a 10%
50
51 (v/v) D₂O/H₂O mixture at ionic strength of 0.10 M (KCl). All CW-EPR spectra were recorded with a
52
53
54
55
56
57
58
59
60

BRUKER EleXsys E500 spectrometer (microwave frequency 9.85 GHz, microwave power 10 mW, modulation amplitude 5 G, modulation frequency 100 kHz. The pH dependent series of isotropic EPR spectra were recorded in a circulating system, at room temperature. A Heidolph Pumpdrive 5101 peristaltic pump was used for circulate the solution from the titration pot through a capillary tube into a Bruker flat cell placed in the cavity of the instrument. The titrations were carried out under nitrogen atmosphere. EPR spectra were recorded at 1.00 mM Cu(II) and 0.75 mM ligand concentration, and at 1.00 mM CuCl₂ and 1.50 mM ligand concentration, both between pH = 1 – 11.5. The ionic strength of 0.1 M was adjusted with KCl. Before the simulation of the room temperature spectra, the measured spectra were corrected by subtracting the spectra of aqua solution measured in the same circulating system. The series of pH-dependent isotropic EPR spectra recorded in the equimolar solution were simulated by the „two-dimensional” method using the 2D_EPR program⁸¹ and EPR parameters were computed as published previously.^{16,25} Distribution coefficients ($D_{7.4}$) values of complexes **1–6** and **HL¹–HL⁶** were determined by the traditional shake-flask method in *n*-octanol/buffered aqueous solution at pH 7.40 (20 mM HEPES, 0.10 M KCl) at 25.0 ± 0.2 °C as described previously.⁸²

7. Crystallographic Structure Determination. X-ray diffraction quality single crystals of **HL¹**, **HL²**, **HL⁴–HL⁶** were obtained by recrystallization in ethanol, while **1** and **3–6** by slow diffusion of diethyl ether into the DMF and methanolic solution of the complexes, respectively. The measurements were performed on a Bruker X8 APEX-II CCD (**HL¹**, **HL²**, **HL⁴**, **HL⁵**, **1'**, **3–6**), Bruker D8 Venture (**1**) or Gemini (**HL⁶**) diffractometer. Single crystals were positioned at 35, 35, 35, 35 and 55 mm from the detector, and 388, 1110, 946, 1108 and 2935 frames were measured, each for 40, 3, 60, 3 and 32s over 0.5, 0.5, 0.5, 0.5 and 1.0° scan width for **HL¹–HL⁶**, respectively. For Cu(II) complexes **1**, **1'**, **3–6** the single crystals were placed at 24, 35, 35, 33, 35 and 24 mm from the detector, and 8088, 2692, 794, 1212, 1261 and 567 fames were measured, each for 3, 2, 60, 60, 60 and 3s over 0.6, 0.5, 0.5, 0.5, 0.4 and 0.5° scan width, respectively. The data were processed using SAINT or CrysAlis software.^{83,84} Crystal data, data collection parameters, and structure refinement details are given in Tables S11 and S12. The

1 structures were solved by direct methods and refined by full-matrix least-squares techniques. Non-H
2 atoms were refined with anisotropic displacement parameters. H atoms were inserted in calculated
3 positions and refined with a riding model. The morpholine group and the N-piperidinyl unit in one of
4 three crystallographically independent molecules in the asymmetric unit were found to be disordered
5 over two positions with s.o.f. 0.5:0.5 and 0.6:0.4 in **3·0.25MeOH**. The morpholine moiety attached to
6 pyridine unit in one of the three crystallographically independent molecules of **4·0.58MeOH** was found
7 to be disordered over two positions with s.o.f. 0.7:0.3, while one molecule of methanol over two
8 positions with s.o.f. 0.75:0.25. The positional parameters of disordered atoms were refined by using
9 PART, DFIX and SADI tools implemented in SHELX. The following computer programs and hardware
10 were used: structure solution, *SHELXS-2014* and refinement, *SHELXL-2014*;⁸⁵ molecular diagrams,
11 ORTEP;⁸⁶ computer, Intel CoreDuo. CCDC 1850567–1850577.

12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27 **8. Electrochemistry and spectroelectrochemistry.** Cyclic voltammetric experiments were performed
28 as described previously.⁵³ The cyclic voltammograms were measured in the cathodic region in different
29 solvents (DMSO, methanol, DMSO/H₂O). The analytical purity grade LiClO₄ (Sigma-Aldrich) and
30 distilled and deionized water were used for preparation of 1 mM aqueous solutions of the investigated
31 complexes **1–6**. EPR spectra were recorded with the EMX plus. *In situ* ultraviolet-visible-near-infrared
32 (UV–vis–NIR) spectroelectrochemical measurements were performed on a spectrometer (Avantes,
33 Model AvaSpec-2048x14-USB2 in the spectroelectrochemical cell kit (AKSTCKIT3) with the Pt-
34 microstructured honeycomb working electrode, purchased from Pine Research Instrumentation. The cell
35 was positioned in the CUV–UV Cuvette Holder (Ocean Optics) connected to the diode-array
36 UV–vis–NIR spectrometer by optical fibers. UV–vis–NIR spectra were processed using the AvaSoft 7.7
37 software package. Halogen and deuterium lamps were used as light sources (Avantes, Model AvaLight-
38 DH-S-BAL). The *in situ* EPR spectroelectrochemical experiments were carried out under an argon
39 atmosphere in the EPR flat cell equipped with a large platinum mesh working electrode. The freshly
40 prepared solutions were carefully purged with argon and the electrolytic cell was polarized in the
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

galvanostatic mode directly in the cylindrical EPR cavity TM-110 (ER 4103 TM) and the EPR spectra were measured in situ.

9. Cell lines and culture conditions. Human ovarian carcinoma cells A2780 and A2780cisR, and human embryonic kidney HEK293 were obtained from ATCC. A2780 and A2780cisR cells were cultured in RPMI 1640 medium containing 10% fetal bovine serum (FBS). HEK293 were cultured in DMEM medium containing 10% FBS. All cells were grown in tissue culture 25 cm² flasks (BD Biosciences, Singapore) at 37 °C in a humidified atmosphere of 95% air and 5% CO₂. All drug stock solutions were prepared in sterile water. The amount of Cu was determined by ICP-OES. All compounds were soluble in water; more specifically, the solubility of **1**, **2** and **5** was moderate and did not exceed 2 mM, whereas **3** was less soluble (0.3 mM) in water.

10. Inhibition of cell viability assay. The cytotoxicity of the compounds was determined by colorimetric microculture assay (MTT assay, MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) as described previously.⁵³

11. Cellular accumulation. Cellular accumulation of **1–6** was determined in A2780 cells. Cells were seeded into Cellstar 6-well plates (Greiner Bio-one) at a density of 60 × 10⁴ cells/well (2 mL per well). After the cells were allowed to resume exponential growth for 24 h, they were exposed to **1–6** at 1 μM for 24 h at 37 °C. The cells were washed twice with 1 mL of PBS and lysed with RIPA lysis buffer for 5–10 min at 4 °C. The cell lysates were scraped from the wells and transferred to separate 1.5 mL microtubes. The supernatant was then collected after centrifugation (13 000 rpm, 4 °C for 15 min) and total protein content of each sample was quantified via Bradford's assay. Cell lysates were transferred to 2 mL glass vials and then digested with ultrapure 65% HNO₃ at 100 °C for 24 h. The resulting solution was diluted to 1 mL (2–4% v/v HNO₃) with ultrapure Milli-Q water. Cu content of each sample was quantified by ICP-MS. In was used as an internal standard. Cu and In were measured at *m/z* 64 and *m/z* 115, respectively. Metal standards for calibration curve (0, 0.5, 1, 2, 5, 10, 20, 40 ppb) were freshly prepared before each measurement. All readings were made in triplicates in He mode. For temperature-

1
2 dependent cellular accumulation experiments, A2780 cells were seeded into 35×10 mm tissue culture
3
4 plates at a density of 60×10⁴ cells/plate. After the cells were allowed to resume exponential growth for
5
6 24 h, they were exposed to **2** at 3 μM for 10, 30, 60 and 120 min at 37 and 4 °C. The subsequent analysis
7
8 was performed as described above. For energy-dependent experiments, A2780 cells were seeded into
9
10 35×10 mm tissue culture plates at a density of 1×10⁶ cells/plate. After the cells were allowed to resume
11
12 exponential growth for 24 h, they were pre-incubated with oligomycin (5 μM) for 1 h or 4 h or with
13
14 cycloheximide (100 μM) for 4 h and further co-incubated with 3 μM of **2** at 37 °C. To induce total
15
16 starvation, after the cells were allowed to resume exponential growth for 24 h, RPMI media was replaced
17
18 with Hanks' Balanced Salt Solution (HBSS) and cells were pre-incubated in HBSS for 1 h and further
19
20 incubated with 3 μM of **2** for 1 h at 37 °C. The subsequent analysis was performed as described above.
21
22
23
24

25 **12. Western blot analysis.** A2780 cells were seeded into Cellstar 6-well plates (Greiner Bio-One) at a
26
27 density of 60 × 10⁴ cells/well (2 mL per well). After the cells were allowed to resume exponential growth
28
29 for 24 h, they were exposed to **HL**² and **2** at different concentrations for 24 h. The experiment was
30
31 performed essentially as described previously.⁵³ The membranes were blocked in 5% BSA (w/v) in
32
33 TBST wash buffer for 1 h and subsequently incubated with the appropriate primary antibodies in 5%
34
35 BSA (w/v) in TBST wash buffer (actin antibody) at 4 °C overnight. The membranes were washed with
36
37 a wash buffer 3 times for 5 min. After incubation with horseradish peroxidase-conjugated secondary
38
39 antibodies (room temperature, 1.5 h), the membranes were washed with a wash buffer 4 times for 5 min.
40
41 Immune complexes were detected with Luminata HRP substrates and analyzed using enhanced
42
43 chemiluminescence imaging. Actin was used as a loading control. The following antibodies were used:
44
45 NRF2 (sc13032) from Santa Cruz Biotechnologies, ECL Antirabbit IgG (NA934 V) and ECL
46
47 Antimouse IgG (NA931) from GE Healthcare Life Sciences, cleaved PARP (Asp214) (D64E10), PARP,
48
49 CHOP (D46F1), BiP (C50B12), IRE1α (14C10), β-actin (13E5), phospho-p44/p42 MAPK (Erk1/2)
50
51 (Thr202/Tyr204) (D13.14.4E), cyclin D1 (92G2), cyclin B1 (D5C10), XIAP antibodies from Cell
52
53
54
55
56
57
58
59
60

1 Signalling Technologies. All antibodies were used at 1 : 500 dilutions except for actin (1 : 10 000), anti-
2 mouse and anti-rabbit (1 : 5000).
3

4
5
6 **13. Annexin V/PI apoptosis assay.** A2780 cells were seeded into Cellstar 12-well plates (Greiner Bio-
7 One) at a density of 20×10^4 cells/well (1 mL per well). The cells were allowed to resume exponential
8 growth for 24 h and subsequently they were exposed to **HL²** and **2** at different concentrations for 24 h.
9 After the supernatant solution was collected in 1.5 mL microtubes, the cells were washed with 100 μ l of
10 trypsin, which was combined with the supernatant. Subsequently, cells were trypsinized with 200 μ l of
11 trypsin for 5 min at 37 °C, 5% CO₂, washed with 200 μ l of PBS and combined with the supernatant. The
12 cells were centrifuged at 2.5×10^3 rpm for 5 min and the pellets were washed once with PBS and
13 resuspended in 500 μ l of Annexin V binding buffer and stained with Annexin V-FITC and PI reagents.
14 The fluorescence was immediately analyzed by flow cytometry. The resulting dot blots were acquired
15 from 10 000 events and quantified using Flowjo software (Flowjo LLC, Ashland, OR, USA).
16
17
18
19
20
21
22
23
24
25
26
27
28

29 **14. Tyrosyl radical reduction in mouse R2 ribonucleotide reductase protein.** The 9.4 GHz EPR
30 spectra were recorded at 30 K on a Bruker EleXsys II E540 EPR spectrometer with an Oxford
31 Instruments ESR900 helium cryostat, essentially as described previously.^{Error! Bookmark not defined.} The
32 small mouse R2 subunit without diferric-tyrosyl cofactor was produced from *E.coli* carrying a mouse
33 R2 cDNA plasmid. The cofactor was further regenerated, resulting in the formation of the cluster with
34 0.38 tyrosyl radical/Fe(III) ratio, which is in agreement with the literature.⁴¹
35
36
37
38
39
40
41
42

43 **15. Molecular docking calculations.** The calculations were performed as described previously.²⁰ The
44 centre of the binding pocket was defined ($x = 102.276$, $y = 87.568$, $z = 80.588$)⁸⁷ with 10 Å radius. The
45 basic amino acids lysine and arginine were defined as protonated. Furthermore, aspartic and glutamic
46 acids were assumed to be deprotonated. The GoldScore (GS),³⁷ ChemScore (CS),^{88,89} Chem Piecewise
47 Linear Potential (ChemPLP)⁹⁰ and Astex Statistical Potential (ASP)⁹⁰ scoring functions were
48 implemented to validate the predicted binding modes and relative energies of the ligands using the
49 GOLD v5.4 software suite. The parameter file for GS was augmented for Cu according to Sciortino et
50
51
52
53
54
55
56
57
58
59
60

1
2 al.³⁸ The QikProp 4.6⁹¹ and Marvin software package⁹² was used to calculate the molecular descriptors
3
4 of the compounds. The reliability of QikProp is established for the molecular descriptors.⁹³
5

6 **16. Bacterial Strains and antibacterial activity.** *Wild-type Pseudomonas aeruginosa PAO1 strain*
7
8 *CECT 4122 (ATCC 15692)* and *Staphylococcus aureus CECT 86 (ATCC 12600)* were obtained from the
9
10 Spanish Type Culture Collection (CECT). All strains were routinely cultivated in TSB medium (Sharlab,
11
12 Spain) at 37 °C. Minimal inhibitory concentration (MIC) assays were determined by the microdilution
13
14 method using TSB broth following the method described by the Clinical and Laboratory standards
15
16 Institute.⁹⁴ In brief, compounds were diluted in a 96-well microtiter plate (tissue culture-treated
17
18 polystyrene; Costar 3595, Corning Inc., Corning, NY) to a final concentration ranging from 0.1 to 100
19
20 µg/mL. A 100-µl aliquot of the bacterial suspension (around 5×10^5 colony forming units/mL
21
22 (CFU/mL)) was inoculated, incubated at 37 °C for 8 h at 150 rpm, and absorbance at 550 nm was read
23
24 every 15 min in an Infinity 200 Pro microplate reader (Tecan). The MIC₁₀₀ was determined as the lowest
25
26 concentration that completely inhibited bacterial growth, and MIC₅₀ in which bacterial growth was
27
28 inhibited at 50%.
29
30
31
32
33

34 **17. Bacterial viability test analysis.** Cultures of *S. aureus* and *P. aeruginosa* were diluted in fresh TSB
35
36 medium and grown overnight to the beginning of exponential phase (A₅₅₀ 0.3) and different compounds
37
38 were added. After 3 h of incubation at 37 °C in shaking conditions, cells were harvested and stained
39
40 using the LIVE/DEAD BactLight Bacterial Viability Kit (Thermofisher) for 30 min. Fluorescent bacteria
41
42 were visualized by a Nikon inverted fluorescent microscope ELIPSE Ti-S/L100 (Nikon) coupled with a
43
44 DS-Qi2 Nikon camera.
45
46
47
48
49

50 ASSOCIATED CONTENT

51
52 **Supporting Information Available:** Synthetic details, atom numbering scheme for NMR spectra
53
54 (Scheme 1), ORTEP views of **HL**¹, **HL**², **HL**⁴⁻⁶ (Figure S1), portion of the crystal structure of **6** (Figure
55
56 S2), low field region of the ¹H NMR spectra of **HL**¹ recorded at pH 0.75–12.50 (Figure S3),
57
58
59
60

1 concentration distribution curves of **HL**¹ (Figure S4), UV–vis and EPR spectra for Cu(II) containing
2 systems (Figures S5–S7), cyclic voltammograms and UV–vis spectra of **1–6** and one of the proligands
3 (Figures S8–S11), plot with potential dependence of UV–vis spectra of **2** (Figure S12), concentration–
4 effect curves (Figure S13), hydrogen binding of **5** to R2 protein (Figure S14), EPR spectrum of R2 RNR
5 tyrosyl radical, complex formation reactions of Fe^{III} and Fe^{II} with **HL**² and **HL**⁵ monitored by UV–vis
6 spectroscopy (Figure S15), ESI MS spectrum of [Fe^{III}(HL⁵)]⁺ (Figure S16), selected bond distances and
7 angles in Cu(II) complexes (Tables S1 and S2), proton dissociation constants for HL¹ (Table S3),
8 cumulative stability and proton dissociation constants of Cu(II) complexes of HL¹ (Table S4), formation
9 constants for Cu(II)–HL¹ complexes (Table S5), electrochemical data for **1–6** (Table S6), Molecular
10 descriptors for **HL**¹–**HL**⁶ and **1–6** (Table S7), details of molecular docking calculations (Table S8),
11 analytical data (Tables S9 and S10), details of data collection and refinement of proligands (Table S11)
12 and Cu(II) complexes (Table S12). Molecular formula strings (CSV). This material is available free of
13 charge via the Internet at <http://pubs.acs.org>.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 Author Information

35 Corresponding Authors

36 * E-mail: maria.babak@nus.edu.sg (M.V.B).

37 * E-mail: vladimir.arion@univie.ac.at (V.B.A.).

38 ORCID

39 Vladimir B. Arion: 0000-0002-1895-6460

40 Maria V. Babak: 0000-0002-2009-7837

41 Eleonora Afanasenko: 0000-0003-0434-1753

42 Éva A. Enyedy: 0000-0002-8058-8128

43 Orsolya Dömötör: 0000-0001-8736-3215

44 Nóra V. May: 0000-0003-4770-4681

Jóhannes Reynisson: 0000-0003-4147-9512

Acknowledgments. Austrian Science Fund (FWF) is acknowledged for the grant no. P28223-N34. This work was supported in part by grants to ET from the Spanish Ministerio de Economía y Competitividad (MINECO / FEDER) (BIO2015-63557-R), Generalitat de Catalunya (2014 SGR01260 and CERCA programme), the Catalan and Spanish Cystic Fibrosis foundations and La Caixa Foundation. This work was also supported by the National Research, Development and Innovation Office FK 124240 project, and the J. Bolyai Research Scholarship of the Hungarian Academy of Sciences (ÉAE and NVM). PR and DD acknowledge the support of Slovak Research and Development Agency (APVV-15-0053) and Slovak Scientific Grant Agency VEGA (1/0416/17). This work was supported by the National University of Singapore (NUS), Department of Pharmacy (C148-000-003-001 (FYP)). We thank A. Roller for collection of X-ray data.

ABBREVIATIONS

TSC, thiosemicarbazone, COTI-2, (*E*)-*N'*-(6,7-dihydroquinolin-8(5*H*)-ylidene)-4-(pyridine-2-yl)piperazine-1-carbothiohydrazide, DpC, di-2-pyridylketone 4-cycloheptyl-4-methyl-3-thiosemicarbazone, ROS, reactive oxygen species, GSH, glutathione, UPR, unfolded protein response, TEMED, tetramethylethylenediamine, PI, propidium iodide, FBS, Foetal Bovine Serum, BSA, Bovine Serum Albumine, HBSS, Hank's Balanced Salt Solution, PS, phosphatidylserine, KDS, known drug space.

Accession Codes

PDB ID of the complexes of Triapine and **5** docked in mouse R2 protein: 1w68-5-T. Authors will release the atomic coordinates upon article publication.

References

- (1) Chabner, B. A.; Roberts, T. G. Chemotherapy and the war on cancer. *Nat. Rev. Cancer* **2005**, *5*, 65–72.
- (2) Inagaki, J.; Rodriguez, V.; Bodey, G. P. Proceedings: causes of death in cancer patients. *Cancer* **1974**, *33*, 568–573.
- (3) Alibek, K.; Bekmurzayeva, A.; Mussabekova, A.; Sultankulov, B. Using antimicrobial adjuvant therapy in cancer treatment: a review. *Infect. Agent Cancer* **2012**, *7*: 33, 10 pp.
- (4) Kardas, J.; Buraczewska, A. The use of antibiotic prophylaxis in patients with solid tumors – when and to whom? *Oncol. Clin. Pract.* **2016**, *12*, 128–135.
- (5) Benharroch, D.; Osyntsov, L. Infectious diseases are analogous with cancer. Hypothesis and implications. *J. Cancer* **2012**, *3*, 117–121.
- (6) Elledge, S. J.; Zhou, Z.; Allen, J. B. Ribonucleotide reductase: regulation, regulation, regulation. *Trends Biochem. Sci.* **1992**, *17*, 119–123.
- (7) Torrents, E. Ribonucleotide reductases: essential enzymes for bacterial life. *Frontiers in Cellular and Infection Microbiology*, **2014**, *4*, 52/1-52/9.
- (8) Beraldo, H.; Gambino, D. The wide pharmacological versatility of semicarbazones, thiosemicarbazones and their metal complexes. *Mini-Rev. Med. Chem.* **2004**, *4*, 31–39.
- (9) Knox, J. J.; Hotte, S. J.; Kollmannsberger, C.; Winkvist, E.; Fisher, B.; Eisenhauer, E. A. Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161). *Invest. New Drugs* **2007**, *25*, 471–477.
- (10) Nutting, C. M.; van Herpen, C. M. L.; Miah, A. B.; Bhide, S. A.; Machiels, J.-P.; Buter, J.; Kelly, C.; de Raucourt, D.; Harrington, K. J. Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma. *Ann. Oncol.* **2009**, *20*, 1275–1279.

- 1
2
3 (11) Traynor, A. M.; Lee, J.-W.; Bayer, G. K.; Tate, J. M.; Thomas, S. P.; Mazurczak, M.; Graham, D.
4
5 L.; Kolesar, J. M.; Schiller, J. H. A phase II trial of Triapine (NSC# 663249) and Gemcitabine as second
6
7 line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group study 1503.
8
9 *Invest. New Drugs* **2010**, *28*, 91–97.
- 10
11 (12) Stacy, A. E.; Palanimuthu, D.; Bernhardt, P. V.; Kalinowski, D. S.; Jansson, P. J.; Richardson, D.
12
13 R. Structure-activity relationships of di-2-pyridylketone, 2-benzoylpyridine, and 2-acetylpyridine
14
15 thiosemicarbazones for overcoming Pgp-mediated drug resistance. *J. Med. Chem.* **2016**, *59*, 8601–8620.
- 16
17 (13) <https://clinicaltrials.gov/ct2/show/NCT02688101> (accessed Feb. 23, 2016).
- 18
19 (14) Salim, K. Y.; Danter, W. R.; Maleki, V. S.; Koropatnick, J. COTI-2, a novel small molecule that is
20
21 active against multiple human cancer cell lines in vitro and in vivo. *Oncotarget* **2016**, *7*, 41363–41379.
- 22
23 (15) West, D. X.; Liberta, A. E.; Padhye, S. B.; Chikate, R. C.; Sonawane, P. B.; Kumbhar, A. S.;
24
25 Yerande, R. G. Thiosemicarbazone complexes of copper(II): structural and biological studies. *Coord.*
26
27 *Chem. Rev.* **1993**, *123*, 49–71.
- 28
29 (16) Bacher, F.; Dömötör, O.; Kaltenbrunner, M.; Mojovic, M.; Popovic-Bijelic, A.; Gräslund, A.;
30
31 Ozarowski, A.; Filipovic, L.; Radulovic, S.; Enyedy, E. A.; Arion, V. B., Effects of terminal
32
33 dimethylation and metal coordination of proline-2-formylpyridine thiosemicarbazone hybrids on
34
35 lipophilicity, antiproliferative activity, and hR2 RNR inhibition. *Inorg. Chem.* **2014**, *53*, 12595–12609.
- 36
37 (17) Milunovic, M. N. M.; Enyedy, E. A.; Nagy, N. V.; Kiss, T.; Trondl, R.; Jakupec, M. A.; Keppler,
38
39 B. K.; Krachler, R.; Novitchi, G.; Arion, V. B. L- and D-proline thiosemicarbazone conjugates:
40
41 coordination behavior in solution and the effect of copper(II) coordination on their antiproliferative
42
43 activity. *Inorg. Chem.* **2012**, *51*, 9309–9321.
- 44
45 (18) Bacher, F.; Dömötör, O.; Chugunova, A.; Nagy, N. V.; Filipovic, L.; Radulovic, S.; Enyedy, E. A.;
46
47 Arion, V. B. Strong effect of copper(II) coordination on antiproliferative activity of thiosemicarbazone-
48
49 piperazine and thiosemicarbazone-morpholine hybrids. *Dalton Trans.* **2015**, *44*, 9071–9090.
- 50
51
52
53
54
55
56
57
58
59
60

- (19) Dobrova, A.; Platzer, S.; Bacher, F.; Milunovic, M. N. M.; Dobrov, A.; Spengler, G.; Enyedy, E. A.; Novitchi, G.; Arion, V. B. Structure-antiproliferative activity studies on L-proline- and homoproline-4*N*-pyrrolidine-3-thiosemicarbazone hybrids and their nickel(II), palladium(II) and copper(II) complexes. *Dalton Trans.* **2016**, *45*, 13427–13439.
- (20) Zaltariov, M. F.; Hammerstad, M.; Arabshahi, H. J.; Jovanovic, K.; Richter, K. W.; Cazacu, M.; Shova, S.; Balan, M.; Andersen, N. H.; Radulovic, S.; Reynisson, J.; Andersson, K. K.; Arion, V. B., New iminodiacetate-thiosemicarbazone hybrids and their copper(II) complexes are potential ribonucleotide reductase R2 inhibitors with high antiproliferative activity. *Inorg. Chem.* **2017**, *56*, 3532–3549.
- (21) Naim, M. J.; Alam, O.; Alam, M. J.; Alam, P.; Shrivastava, N. A review on pharmacological profile of morpholine derivatives. *Int. J. Pharmacol. Pharm. Sci.* **2016**, *3*, 40–51.
- (22) Boehm, M. F.; Heyman, R. A. Compounds Having Selective Activity for Retinoid X Receptors, and Means for Modulation of Processes Mediated by Retinoid X Receptors. US7655699 B1, 2010.
- (23) Warr, R. J.; Willis, A. C.; Wild, S. B. Inorganic asymmetric synthesis: asymmetric synthesis of a two-bladed propeller, octahedral metal complex. *Inorg. Chem.* **2006**, *45*, 8618–8627.
- (24) Dawson, M. I.; Chan, R.; Hobbs, P. D.; Chao, W. R.; Schiff, L. J. Aromatic retinoic acid analogues. 2. Synthesis and pharmacological activity. *J. Med. Chem.* **1983**, *26*, 1282–1293.
- (25) Dömötör, O.; May, N. V.; Pelivan, K.; Kiss, T.; Keppler, B. K.; Kowol, C. R.; Enyedy, É. A. A comparative study of α -*N*-pyridyl thiosemicarbazones: spectroscopic properties, solution stability and copper(II) complexation. *Inorg. Chim. Acta* **2018**, *472*, 264–275.
- (26) Enyedy, E. A.; Zsigo, E.; Nagy, N. V.; Kowol, C. R.; Roller, A.; Keppler, B. K.; Kiss, T. Complex-formation ability of salicylaldehyde thiosemicarbazone towards Zn^{II}, Cu^{II}, Fe^{II}, Fe^{III} and Ga^{III} ions. *Eur. J. Inorg. Chem.* **2012**, *2012*, 4036–4047.

- (27) Kowol, C. R.; Heffeter, P.; Miklos, W.; Gille, L.; Trondl, R.; Cappellacci, L.; Berger, W.; Keppler, B. K. Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds. *J. Biol. Inorg. Chem.* **2012**, *17*, 409–423.
- (28) Goeschl, S.; Varbanov, H. P.; Theiner, S.; Jakupec, M. A.; Galanski, M.; Keppler, B. K. The role of the equatorial ligands for the redox behavior, mode of cellular accumulation and cytotoxicity of platinum(IV) prodrugs. *J. Inorg. Biochem.* **2016**, *160*, 264–274.
- (29) Primik, M. F.; Mülgassner, G.; Jakupec, M. A.; Zava, O.; Dyson, P. J.; Arion, V. B.; Keppler, B. K. Highly cytotoxic copper(II) complexes with modified paullone ligands. *Inorg. Chem.* **2010**, *49*, 302–311.
- (30) Waring, M. J. Lipophilicity in drug discovery. *Expert Opin. Drug Discovery* **2010**, *5*, 235–248.
- (31) Zhu, F.; Logan, G.; Reynisson, J. Wine compounds as a source for HTS screening collections. A feasibility study. *Mol. Inf.* **2012**, *31*, 847–855.
- (32) Los, D. A.; Murata, N. Membrane fluidity and its roles in the perception of environmental signals. *Biochim. Biophys. Acta, Biomembr.* **2004**, *1666*, 142–157.
- (33) Price, K. A.; Crouch, P. J.; Volitakis, I.; Paterson, B. M.; Lim, S.; Donnelly, P. S.; White, A. R. Mechanisms controlling the cellular accumulation of copper bis(thiosemicarbazonato) complexes. *Inorg. Chem.* **2011**, *50*, 9594–9605.
- (34) Merlot, A. M.; Pantarat, N.; Menezes, S. V.; Sahni, S.; Richardson, D. R.; Kalinowski, D. S. Cellular uptake of the antitumor agent Dp44mT occurs via a carrier/receptor-mediated mechanism. *Mol. Pharmacol.* **2013**, *84*, 911–924.
- (35) Sugano, K.; Kansy, M.; Artursson, P.; Avdeef, A.; Bendels, S.; Di, L.; Ecker, G. F.; Faller, B.; Fischer, H.; Gerebtzoff, G.; Lennernaes, H.; Senner, F. Coexistence of passive and carrier-mediated processes in drug transport. *Nat. Rev. Drug Discovery* **2010**, *9*, 597–614.

- 1
2
3 (36) Strand, K. R.; Karlsen, S.; Kolberg, M.; Rohr, A. K.; Goerbitz, C. H.; Andersson, K. K. Crystal
4 structural studies of changes in the native dinuclear iron center of ribonucleotide reductase protein R2
5 from mouse. *J. Biol. Chem.* **2004**, *279*, 46794–46801.
6
7
8
9
10 (37) Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic
11 algorithm for flexible docking. *J. Mol. Biol.* **1997**, *267*, 727–748.
12
13
14 (38) Sciortino, G.; Rodriguez-Guerra Pedregal, J.; Lledos, A.; Garribba, E.; Marechal, J.-D. Prediction
15 of the interaction of metallic moieties with proteins: an update for protein-ligand docking techniques. *J.*
16 *Comput. Chem.* **2018**, *39*, 42–51.
17
18
19
20
21 (39) Gräslund, A.; Ehrenberg, A.; Thelander, L. Characterisation of the free radical of mammalian
22 ribonucleotide reductase. *J. Biol. Chem.* **1982**, *257*, 5711–5715.
23
24
25
26 (40) Thelander, L.; Graslund, A. Mechanism of inhibition of mammalian ribonucleotide reductase by the
27 iron chelate of 1-formylisoquinoline thiosemicarbazone. *J. Biol. Chem.* **1983**, *258*, 4063–4066.
28
29
30
31 (41) Popović-Bijelić, A.; Kowol, C. R.; Lind, M. E.; Luo, J.; Himo, F.; Enyedy, E. A.; Arion, V. B.;
32 Gräslund, A. Ribonucleotide reductase inhibition by metal complexes of Triapine (3-aminopyridine-2-
33 carboxaldehyde thiosemicarbazone): a combined experimental and theoretical study. *J. Inorg. Biochem.*
34 **2011**, *105*, 1422–1431.
35
36
37
38
39 (42) Enyedy, A. E.; Primik, M. F.; Kowol, C. R.; Arion, V. B.; Kiss, T.; Keppler, B. K. Interaction of
40 Triapine and related thiosemicarbazones with iron(III)/(II) and gallium(III): a comparative solution
41 equilibrium study. *Dalton Trans.* **2011**, *40*, 5895–5905.
42
43
44
45
46 (43) Mullen, P. PARP cleavage as a means of assessing apoptosis. *Methods Mol. Med.* **2004**, *88*,
47 171–181.
48
49
50
51 (44) Finch, R. A.; Liu, M. C.; Cory, A. H.; Cory, J. G.; Sartorelli, A. C. Triapine (3-aminopyridine-2-
52 carboxaldehyde thiosemicarbazone (3-AP)). An inhibitor of ribonucleotide reductase with antineoplastic
53 activity. *Adv. Enzyme Regul.* **1999**, *39*, 3–12.
54
55
56
57
58
59
60

- 1
2
3 (45) Finch, R. A.; Liu, M.; Grill, S. P.; Rose, W. C.; Loomis, R.; Vasquez, K. M.; Cheng, Y.; Sartorelli,
4
5 A. C. Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone). A potent inhibitor of
6
7 ribonucleotide reductase activity with broad spectrum of antitumor activity. *Biochem. Pharm.* **2000**, *59*,
8
9 983–991.
10
11
12 (46) Yu, Y.; Wong, J.; Lovejoy, D. B.; Kalinowski, D. S.; Richardson, D. R. Chelators at the cancer
13
14 coalface. Desferrioxamine to triapine and beyond. *Clin. Cancer Res.* **2006**, *12*, 6876–6883.
15
16
17 (47) Shao, J.; Zhou, B.; Di Bilio, A. J.; Zhu, L.; Wang, T.; Qi, C.; Shih, J.; Yen, Y. A ferrous-triapine
18
19 complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase.
20
21 *Mol. Cancer Ther.* **2006**, *5*, 586–592.
22
23
24 (48) Kowol, C. R.; Trondl, R.; Heffeter, P.; Arion, V. B.; Jakupec, M. A.; Roller, A.; Galanski, M.;
25
26 Berger, W.; Keppler, B. K. Impact of metal coordination on cytotoxicity of 3-aminopyridine-2-
27
28 carboxaldehyde thiosemicarbazone (triapine) and novel insights into terminal demethylation. *J. Med.*
29
30 *Chem.* **2009**, *52*, 5032–5043.
31
32
33 (49) Yu, Y.; Gutierrez, E.; Kovacevic, Z.; Saletta, F.; Obeidy, P.; Suryo Rahmanto, Y.; Richardson, D.
34
35 R. Iron chelators for the treatment of cancer. *Curr. Med. Chem.* **2012**, *19*, 2869–2702.
36
37
38 (50) Merlot, A. M.; Kalinowski, D. S.; Richardson, D. R. Novel chelators for cancer treatment: where
39
40 are we now? *Antioxid. Red. Signal* **2013**, *18*, 973–1006.
41
42
43 (51) Aye, Y.; Long, M. J. C.; Stubbe, J. Mechanistic studies of semicarbazide triapine targeting human
44
45 ribonucleotide reductase in vitro and in mammalian cells. Tyrosyl radical quenching not involving
46
47 reactive oxygen species. *J. Biol. Chem.* **2012**, *287*, 35768–35778.
48
49
50 (52) Pandeya, S. N.; Sriram, D.; Nath, G.; DeClercq, E. Synthesis, antibacterial, antifungal and anti-HIV
51
52 activities of Schiff and Mannich bases derived from isatin derivatives and *N*-[4-(4'-chlorophenyl)thiazol-
53
54 2-yl] thiosemicarbazide]. *Eur. J. Pharm. Sci.* **1999**, *9*, 25–31.
55
56
57
58
59
60

- (53) Sirbu, A.; Palamarciuc, O.; Babak, M. V.; Lim, J. M.; Ohui, K.; Enyedy, E. A.; Shova, S.; Darvasiova, D.; Rapta, P.; Ang, W. H.; Arion, V. B. Copper(II) thiosemicarbazone complexes induce marked ROS accumulation and promote nrf2-mediated antioxidant response in highly resistant breast cancer cells. *Dalton Trans.* **2017**, *46*, 3833–3847.
- (54) Yu, Y.; Kalinowski, D. S.; Kovacevic, Z.; Siafakas, A. R.; Jansson, P. J.; Stefani, C.; Lovejoy, D. B.; Sharpe, P. C.; Bernhardt, P. V.; Richardson, D. R. Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. *J. Med. Chem.* **2009**, *52*, 5271–5294.
- (55) Antholine, W.; Knight, J.; Whelan, H.; Petering, D. H. Studies of the reaction of 2-formylpyridine thiosemicarbazone and its iron and copper complexes with biological systems. *Mol. Pharmacol.* **1977**, *13*, 89–98.
- (56) Chaston, T.B.; Lovejoy, D.B.; Watts, R.N.; Richardson, D.R. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. *Clin Cancer Res.* **2003** *9*, 402-414
- (57) Yu, Y.; Kovacevic, Z.; Richardson, D. R. Tuning cell cycle regulation with an iron key. *Cell Cycle* **2007**, *6*, 1982–1994.
- (58) Nurtjahja-Tjendraputra, E.; Fu, D.; Phang, J. M.; Richardson, D.R. Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. *Blood* **2007**, *109*, 4045–4054.
- (59) Thelander, L.; Graslund, A.; Thelander, M. Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: Possible regulation mechanism. *Biochem. Biophys. Res. Commun.* **1983**, *110*, 859–865.
- (60) Lui, G. Y. L.; Kovacevic, Z.; Menezes, S. V.; Kalinowski, D. S.; Merlot, A. M.; Sahni, S.; Richardson, D. R. Novel thiosemicarbazones regulate the signal transducer and activator of transcription

1
2
3 3 (STAT3) pathway: inhibition of constitutive and interleukin 6-induced activation by iron depletion.

4
5 *Mol. Pharmacol.* **2015**, *87*, 543–560.

6
7 (61) Yu, Y.; Rahmanto, Y. S.; Richardson, D. R. Bp44mT: an orally active iron chelator of the
8 thiosemicarbazone class with potent anti-tumour efficacy. *Br. J. Pharmacol.* **2012**, *165*, 148–166.

9
10 (62) Karin, M. The regulation of AP-1 activity by mitogen-activated protein kinases. *J. Biol. Chem.* **1995**,
11 *270*, 16483–16486.

12
13 (63) Lee, S.-K.; Jang, H.-J.; Lee, H.-J.; Lee, J.; Jeon, B.-H.; Jun, C.-D.; Lee, S.-K.; Kim, E.-C. p38 and
14 ERK MAP kinase mediates iron chelator-induced apoptosis and –suppressed differentiation of
15 immortalized and malignant human oral keratinocytes. *Life Sciences* **2006**, *79*, 1419–1427.

16
17 (64) Moon, S. K.; Jung, S. Y.; Choi, Y. H.; Lee, Y.C.; Patterson, C.; Kim, C. H. PDTC, metal chelating
18 compound, induces G1 phase cell cycle arrest in vascular smooth muscle cells through inducing p21Cip1
19 expression: Involvement of p38 mitogen activated protein kinase. *J. Cell Physiol.* **2004**, *198*, 310–323.

20
21 (65) Lane, D. J. R.; Mills, T. M.; Shafie, N. H.; Merlot, A. M.; Saleh Moussa, R.; Kalinowski, D. S.;
22 Kovacevic, Z.; Richardson, D. R. Expanding horizons in iron chelation and the treatment of cancer: role
23 of iron in the regulation of ER stress and the epithelial-mesenchymal transition. *Biochim. Biophys. Acta*
24 *Rev. Cancer* **2014**, *1845*, 166–181.

25
26 (66) Lane, D. J. R.; Saletta, F.; Rahmanto, Y. S.; Kovacevic, Z.; Richardson, D. R. N-myc downstream
27 regulated 1 (NDRG1) is regulated by eukaryotic initiation factor 3a (eIF3a) during cellular stress caused
28 by iron depletion. *PLoS One* **2013**, *8*, e57273.

29
30 (67) Trondl, R.; Flocke, L. S.; Kowol, C. R.; Heffeter, P.; Jungwirth, U.; Mair, G. E.; Steinborn, R.;
31 Enyedy, E. A.; Jakupec, M. A.; Berger, W.; Keppler, B. K. Triapine and a more potent dimethyl
32 derivative induce endoplasmic reticulum stress in cancer cells. *Mol. Pharmacol.* **2014**, *85*, 451–459.

33
34 (68) Merlot, A. M.; Shafie, N. H.; Yu, Y.; Richardson, V.; Jansson, P. J.; Sahni, S.; Lane, D. J. R.;
35 Kovacevic, Z.; Kalinowski, D. S.; Richardson, D. R. Mechanism of the induction of endoplasmic
36

- reticulum stress by the anti-cancer agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT): activation of PERK/eIF2 α , IRE1 α , ATF6 and calmodulin kinase. *Biochem. Pharmacol.* **2016**, *109*, 27–47.
- (69) Fu, Y.; Liu, Y.; Wang, J.; Li, C.; Zhou, S.; Yang, Y.; Zhou, P.; Lu, C.; Li, C., Calcium release induced by 2-pyridinecarboxaldehyde thiosemicarbazone and its copper complex contributes to tumor cell death. *Oncol. Rep.* **2017**, *37*, 1662–1670.
- (70) Lee, A. S. GRP78 induction in cancer: therapeutic and prognostic implications. *Cancer Res.* **2007**, *67*, 3496–3499.
- (71) Pillich, H.; Loose, M.; Zimmer, K-P.; Chakraborty, T. Diverse roles of endoplasmic reticulum stress sensors in bacterial infection. *Molecular and Cellular Pediatrics* **2016**, *3*, 1–6.
- (72) Abuaita, B. M.; Burkholder, K. M.; Boles, B. R.; O’Riordan, M. X. The endoplasmic reticulum stress sensor inositol-requiring enzyme 1 α augments bacterial killing through sustained oxidant production. *mBio* **2015**, *6*, e00705–e00715.
- (73) Li, J.; Sasaki, H.; Sheng, Y. L.; Schneiderman, D.; Xiao, C. W.; Kotsuji, F.; Tsang, B. K. Apoptosis and chemoresistance in human ovarian cancer: is Xiap a determinant? *Biol. Signals Recept.* **2000**, *9*, 122–130.
- (74) Alvero, A. B.; Chen, W.; Sartorelli, A. C.; Schwartz, P.; Rutherford, T.; Mor, G. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) induces apoptosis in ovarian cancer cells. *J. Soc. Gynecol. Invest.* **2006**, *13*, 145–152.
- (75) Karlsson, H.; Fryknas, M.; Strese, S.; Gullbo, J.; Larsson, R.; Sjoblom, T.; Pandzic, T.; Nygren, P.; Westman, G.; Bremberg, U. Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity. *Oncotarget* **2017**, *8*, 30217–30234.

- (76) Bisceglie, F.; Alinovi, R.; Pinelli, S.; Galetti, M.; Pioli, M.; Tarasconi, P.; Mutti, A.; Goldoni, M.; Pelosi, G. Autophagy and apoptosis: studies on the effects of bithiosemicarbazone copper(II) complexes on p53 and p53-null tumour cell lines. *Metallomics* **2016**, *8*, 1255–1265.
- (77) Hancock, C. N.; Stockwin, L. H.; Han, B.; Divelbiss, R. D.; Jun, J. H.; Malhotra, S. V.; Hollingshead, M. G.; Newton, D. L. A copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivo. *Free Radical Biol. Med.* **2011**, *50*, 110–121.
- (78) De, B. M.; Taverna, E.; Bongarzone, I.; Maffioli, E.; Tedeschi, G.; Casalini, P.; Crisafi, F.; Kumar, V.; Polli, D.; Caccia, C. Lipid accumulation in human breast cancer cells injured by iron depletors. *J. Exp. Clin. Cancer Res.* **2018**, *37*, 75.
- (79) Gans, P.; Sabatini, A.; Vacca, A. Investigation of equilibria in solution. Determination of equilibrium constants with HYPERQUAD suite of programmes. *Talanta* **1996**, *43*, 1739–1753.
- (80) Zékány, L.; Nagypál, I. in: *Computational Methods for the Determination of Stability Constants*, ed. D. L. Leggett, Plenum Press, New York, **1985**, p. 291.
- (81) Rockenbauer, A.; Szabó-Plánka, T.; Árkosi, Zs.; Korecz, L. A two-dimensional (magnetic field and concentration) electron paramagnetic resonance method for analysis of multispecies complex equilibrium systems. Information content of EPR spectra. *J. Am. Chem. Soc.* **2001**, *123*, 7646–7654.
- (82) Enyedy, É. A.; Hollender, D.; Kiss, T. Lipophilicity of kinetically labile metal complexes through the example of antidiabetic Zn(II) and VO(IV) compounds. *J. Pharm. Biomed. Anal.* **2011**, *54*, 1073–1081.
- (83) *SAINT-Plus*, version 8.32B and APEX2; Bruker-Nonius AXS Inc.: Madison, WI, 2016.
- (84) *CrysAlis RED*, Version 1.171.36.32; Oxford Diffraction Ltd, 2003.
- (85) Sheldrick, G. M. A short history of SHELX. *Acta Crystallogr., Sect. A: Found. Crystallogr.* **2008**, *64*, 112–122.

- 1
2
3 (86) Burnett, M. N.; Johnson, G. K. ORTEPIII. Report ORNL-6895. OAK Ridge National Laboratory;
4
5 Tennessee, **1996**.
- 6
7 (87) Mooij, W. T. M.; Verdonk, M. L., General and targeted statistical potentials for protein–ligand
8
9 interactions. *Proteins* **2005**, *61*, 272–287.
- 10
11 (88) Eldridge, M. D.; Murray, C.; Auton, T. R.; Paolini, G. V.; Mee, P. M. Empirical scoring functions:
12
13 I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in
14
15 receptor complexes. *J. Comp. Aid. Mol. Design* **1997**, *11*, 425–445.
- 16
17 (89) Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved protein-
18
19 ligand docking using GOLD. *Proteins* **2003**, *52*, 609–623.
- 20
21 (90) Korb, O.; Stuetzle, T.; Exner, T. E. Empirical scoring functions for advanced protein-ligand docking
22
23 with PLANTS. *J. Chem. Inf. Model.* **2009**, *49*, 84–96.
- 24
25 (91) Schrödinger *Small-Molecule Drug Discovery Suite 2015-4: QikProp*, 4.6; 2015.
- 26
27 (92) ChemAxon-Marvin, ChemAxon. Ltd: 15.7.13.0, 2015, <http://www.chemaxon.com>.
- 28
29 (93) Ioakimidis, L.; Thoukydidis, L.; Mirza, A.; Naeem, S.; Reynisson, J., Benchmarking the reliability
30
31 of QikProp. Correlation between experimental and predicted values. *QSAR & Combinatorial Science*
32
33 **2008**, *27*, 445–456.
- 34
35 (94) Clinical and laboratory standards institute. Methods for dilution antimicrobial susceptibility test for
36
37 bacteria that grow aerobically; approved standard, CLSI document M7-A7, 7th ed. *Clinical and*
38
39 *Laboratory Standards Institute, Wayne, PA* **2006**.
- 40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table of Contents graphic

UNIVERSITY OF VIENNA and NATIONAL UNIVERSITY OF SINGAPORE present

DOUBLE IMPACT

starring:
Cu(II) thiosemicarbazone-morpholine hybrids

antibacterial action

anticancer effect

OHUI AFANASENKO BACHER TING ZAFAR BLANCO-CABRA TORRENTS DÓMÓTÓR MAY DARVASIOVA ENYEDY POPOVIĆ-BIJELIĆ REYNISSON RAPTA BABAK PASTORIN ARION